Hologic (HOLX) 10-Q 6 Feb 25 2025 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Dec. 28, 2024	Jan. 31, 2025
Cover [Abstract]
Title of 12(b) Security	Common Stock, $0.01 par value
Document Transition Report	false
Document Quarterly Report	true
Entity Incorporation, State or Country Code	DE
Entity Address, Postal Zip Code	01752
Entity File Number	1-36214
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 28, 2024
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q1
Entity Registrant Name	HOLOGIC, INC
Entity Central Index Key	0000859737
Current Fiscal Year End Date	--09-28
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		224,389,612
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
City Area Code	(508)
Local Phone Number	263-2900
Entity Tax Identification Number	04-2902449
Entity Address, Address Line One	250 Campus Drive,
Entity Address, City or Town	Marlborough,
Entity Address, State or Province	MA
Trading Symbol	HOLX
Security Exchange Name	NASDAQ

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Revenues:
Revenues	$ 1,021.8	$ 1,013.1
Costs of revenues:
Amortization of acquired intangible assets	46	45.5
Gross profit	580.5	567.5
Operating expenses:
Research and development	60.3	66.8
Selling and marketing	166.1	148.9
General and administrative	115.7	111.8
Amortization of acquired intangible assets	4.7	13.3
Impairment of intangible asset	0	4.3
Contingent consideration fair value adjustment	0	1.7
Restructuring charges	3.9	22.5
Operating expenses	350.7	369.3
Income from operations	229.8	198.2
Interest income	24.2	27.9
Interest expense	(30.5)	(26)
Other income (expense), net	24	(8.8)
Income before income taxes	247.5	191.3
Provision (benefit) for income taxes	46.5	(55.2)
Net income	$ 201	$ 246.5
Net income per common share:
Basic (in usd per share)	$ 0.87	$ 1.03
Diluted (in usd per share)	$ 0.87	$ 1.03
Weighted average number of shares outstanding:
Basic (in shares)	230,284	238,627
Diluted (in shares)	232,107	240,214
Product
Revenues:
Revenues	$ 817.9	$ 828.1
Costs of revenues:
Cost of revenue	301.1	307.2
Service
Revenues:
Revenues	203.9	185
Costs of revenues:
Cost of revenue	$ 94.2	$ 92.9

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Statement of Comprehensive Income [Abstract]
Net income	$ 201	$ 246.5
Changes in foreign currency translation adjustment	(54.8)	43
Gain (loss) recognized, net of tax of $0.1 for the three months ended December 28, 2024 on available-for-sale securities	(1.3)	0
Gain (loss) recognized, net of tax of $1.5 for the three months ended December 28, 2024 and $(4.5) for the three months ended December 30, 2023, for interest rate swaps	4.9	(14.2)
Other comprehensive income (loss)	(51.2)	28.8
Comprehensive income	$ 149.8	$ 275.3

Consolidated Statements of Co_2

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Statement of Comprehensive Income [Abstract]
Changes in unrealized holding gains and losses on available-for-sale securities, tax	$ 0.1
Gain (loss) recognized, tax	$ 1.5	$ (4.5)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 28, 2024	Sep. 28, 2024
Current assets:
Cash and cash equivalents	$ 1,782.1	$ 2,160.2
Short-term investments	190.6	173.4
Accounts receivable, less reserves	631.4	600.4
Inventory	707.1	679.8
Prepaid expenses and other current assets	158.3	156.2
Prepaid income taxes	24.1	53.3
Total current assets	3,493.6	3,823.3
Property, plant and equipment, net	537.2	537.8
Intangible assets, net	793.3	844.6
Goodwill	3,422.9	3,443.1
Long-term investments	47.9	96.4
Other assets	433.8	410.8
Total assets	8,728.7	9,156
Current liabilities:
Current portion of long-term debt	46.8	37.5
Accounts payable	236.7	203.8
Accrued expenses	528.1	579.7
Deferred revenue	187.5	212.9
Finance lease obligations	3.3	3.3
Total current liabilities	1,002.4	1,037.2
Long-term debt, net of current portion	2,479.2	2,497.1
Finance lease obligations, net of current portion	11.1	12.2
Deferred income tax liabilities	53.7	59.4
Deferred revenue, net of current portion	12.4	13.8
Other long-term liabilities	396.6	406.3
Stockholders’ equity:
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued	0	0
Common stock, $0.01 par value – 750,000 shares authorized; 301,772 and 301,185 shares issued, respectively	3	3
Additional paid-in-capital	6,259.4	6,244.2
Retained earnings	3,046.8	2,845.8
Treasury stock, at cost – 76,212 and 69,460 shares, respectively	(4,373.2)	(3,851.5)
Accumulated other comprehensive loss	(162.7)	(111.5)
Total stockholders’ equity	4,773.3	5,130
Total liabilities and stockholders’ equity	$ 8,728.7	$ 9,156

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Dec. 28, 2024	Sep. 28, 2024
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (in shares)	1,623,000	1,623,000
Preferred stock, issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	750,000,000	750,000,000
Common stock, issued (in shares)	301,772,000	301,185,000
Treasury stock (in shares)	76,212,000	69,460,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Millions		Total	Accelerated Share Repurchase Agreement	Common Stock	Additional Paid-in Capital	Additional Paid-in Capital Accelerated Share Repurchase Agreement	Retained Earnings	Total	Treasury Stock		Treasury Stock Accelerated Share Repurchase Agreement
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance		$ 5,016.9		$ 3	$ 6,141.2		$ 2,056.3	$ (147.6)	$ (3,036)
Balance (in shares) at Sep. 30, 2023				299,940
Balance (in shares) at Sep. 30, 2023									58,231
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)				124
Exercise of stock options					5
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)				432
Vesting of restricted stock units, net of shares withheld for employee taxes					(16.2)
Stock-based compensation expense		28.7			28.7
Net income		246.5					246.5
Other comprehensive income activity								28.8
Repurchase of common stock (in shares)									2,161	[1]	5,560
Repurchase of common stock			$ (500)			$ (100)			$ (155.9)	[1]	$ (400)
Balance (in shares) at Dec. 30, 2023				300,496
Ending balance at Dec. 30, 2023		4,653.8		$ 3	6,058.7		2,302.8	(118.8)	$ (3,591.9)
Balance (in shares) at Dec. 30, 2023									65,952
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance		4,653.8		$ 3	6,058.7		2,302.8	(118.8)	$ (3,591.9)
Exercise of stock options (in shares)				79
Exercise of stock options					3.2
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)				16
Vesting of restricted stock units, net of shares withheld for employee taxes					(0.1)
Common stock issued under the employee stock purchase plan (in shares)				165
Common stock issued under the employee stock purchase plan					10
Stock-based compensation expense		25.8			25.8
Net income		169.9					169.9
Other comprehensive income activity								(18.2)
Repurchase of common stock (in shares)											1,428
Repurchase of common stock			0			$ 100					$ (100)
Balance (in shares) at Mar. 30, 2024				300,756
Ending balance at Mar. 30, 2024		4,844.4		$ 3	6,197.6		2,472.7	(137)	$ (3,691.9)
Balance (in shares) at Mar. 30, 2024									67,380
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance		4,844.4		$ 3	6,197.6		2,472.7	(137)	$ (3,691.9)
Exercise of stock options (in shares)				24
Exercise of stock options					1.2
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)				7
Vesting of restricted stock units, net of shares withheld for employee taxes					(0.3)
Stock-based compensation expense		14.6			14.6
Net income		194.5					194.5
Other comprehensive income activity								(2.5)
Repurchase of common stock (in shares)	[1]								1,351
Repurchase of common stock	[1]								$ (101)
Balance (in shares) at Jun. 29, 2024				300,787
Ending balance at Jun. 29, 2024		4,950.9		$ 3	6,213.1		2,667.2	(139.5)	$ (3,792.9)
Balance (in shares) at Jun. 29, 2024									68,731
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance		4,950.9		$ 3	6,213.1		2,667.2	(139.5)	$ (3,792.9)
Exercise of stock options (in shares)				196
Exercise of stock options					7.5
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)				18
Vesting of restricted stock units, net of shares withheld for employee taxes					(0.8)
Common stock issued under the employee stock purchase plan (in shares)				184
Common stock issued under the employee stock purchase plan					11.2
Stock-based compensation expense		13.2			13.2
Net income		178.6					178.6
Other comprehensive income activity								28
Repurchase of common stock (in shares)	[1]								729
Repurchase of common stock	[1]								$ (58.6)
Balance (in shares) at Sep. 28, 2024				301,185
Ending balance at Sep. 28, 2024		$ 5,130		$ 3	6,244.2		2,845.8	(111.5)	$ (3,851.5)
Balance (in shares) at Sep. 28, 2024		69,460,000							69,460
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance		$ 5,130		$ 3	6,244.2		2,845.8	(111.5)	$ (3,851.5)
Exercise of stock options (in shares)				118
Exercise of stock options					6.8
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)				469
Vesting of restricted stock units, net of shares withheld for employee taxes					(21.7)
Stock-based compensation expense		30.1			30.1
Net income		201					201
Other comprehensive income activity								(51.2)
Repurchase of common stock (in shares)									3,420	[1]	3,332
Repurchase of common stock			$ (250)						$ (271.7)	[1]	$ (250)
Balance (in shares) at Dec. 28, 2024				301,772
Ending balance at Dec. 28, 2024		$ 4,773.3		$ 3	6,259.4		3,046.8	(162.7)	$ (4,373.2)
Balance (in shares) at Dec. 28, 2024		76,212,000							76,212
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance		$ 4,773.3		$ 3	$ 6,259.4		$ 3,046.8	$ (162.7)	$ (4,373.2)
[1]Includes excise tax on share repurchases.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024		Sep. 28, 2024		Mar. 30, 2024	Dec. 30, 2023
OPERATING ACTIVITIES
Net income	$ 201		$ 178.6		$ 169.9	$ 246.5
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	23.3					29.6
Amortization of acquired intangible assets	50.7					58.8
Stock-based compensation expense	30.1					28.7
Deferred income taxes	(19.5)					(17.6)
Intangible asset impairment charge	0					4.3
Other adjustments and non-cash items	(19.1)					27.5
Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions:
Accounts receivable	(41.7)					(38.2)
Inventories	(36.1)					(13)
Prepaid income taxes	29.2					(70.1)
Prepaid expenses and other assets	13.2					2.6
Accounts payable	36.2					7.2
Accrued expenses and other liabilities	(54.6)					(35.7)
Deferred revenue	(23.4)					(10.6)
Net cash provided by operating activities	189.3					220
INVESTING ACTIVITIES
Acquisition of businesses, net of cash acquired	(0.3)					0
Acquisition of intangible assets	(15.4)					0
Sale of business, net of cash disposed	0					(31.3)
Capital expenditures	(16.8)					(22.7)
Increase in equipment under customer usage agreements	(14.8)					(15.3)
Strategic investments	6					34.5
Maturities of available-for-sale securities	32					0
Other activity	(0.7)					(0.4)
Net cash used in investing activities	(22)					(104.2)
FINANCING ACTIVITIES
Repayment of long-term debt	(9.4)					(259.4)
Repurchases of common stock	(517.3)					(676.8)
Proceeds from issuance of common stock pursuant to employee stock plans	12.2					9.5
Payment of minimum tax withholdings on net share settlements of equity awards	(21.7)					(16.2)
Payments under finance lease obligations	(0.8)					(0.9)
Net cash used in financing activities	(537)					(943.8)
Effect of exchange rate changes on cash and cash equivalents	(8.4)					4.4
Net decrease in cash and cash equivalents	(378.1)					(823.6)
Cash and cash equivalents, beginning of period	2,160.2	[1]			$ 1,932.1	2,755.7	[1]
Cash and cash equivalents, end of period	$ 1,782.1		$ 2,160.2	[1]		$ 1,932.1
[1]Includes $33.2 million of cash recorded in assets held-for-sale - current assets as of September 30, 2023.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) $ in Millions	Sep. 28, 2024 USD ($)
Disposed of by Sale | SSI Ultrasound Imaging Business
Cash	$ 33.2

Basis of Presentation

Basis of Presentation	3 Months Ended
	Dec. 28, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”) for annual financial statements. These unaudited financial statements should be read in conjunction with the consolidated financial statements and related notes for the fiscal year ended September 28, 2024 included in the Company’s annual report on Form 10-K filed with the SEC on November 27, 2024. In the opinion of management, the unaudited financial statements and notes contain all adjustments (consisting of normal recurring accruals and all other necessary adjustments) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented. The unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three months ended December 28, 2024 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 27, 2025. Subsequent Events Consideration The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events, except as described below, affecting the unaudited consolidated financial statements as of and for the three months ended December 28, 2024. On January 2, 2025, the Company completed the acquisition of Gynesonics, Inc. (“Gynesonics”) for a purchase price of approximately $350.0 million, subject to working capital and other customary adjustments. Gynesonics, located in Redwood City, California, develops a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. Gynesonics will be included in the GYN Surgical reportable segment.

Leases

Leases	3 Months Ended
	Dec. 28, 2024
Leases [Abstract]
Leases	Leases Lessor Activity - Leases where Hologic is the Lessor
Leases	Leases Lessor Activity - Leases where Hologic is the Lessor

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Dec. 28, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]	Fair Value Measurements Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis The Company has investments in money market funds, United States Treasury securities and commercial paper that are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents, and Short term and Long term investments on the Consolidated Balance Sheets, which is determined based on maturities at the time of purchase and re-evaluated at each balance sheet date. The Company also has investments in derivative instruments comprised of interest rate swaps, forward foreign currency contracts and foreign currency option contracts (including collars). These instruments were valued using analyses obtained from independent third-party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of these derivative contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 11 for further discussion and information on derivative contracts. In addition, the Company has a contingent consideration liability that is recorded at fair value, which is based on Level 3 inputs. The following table summarizes certain fair value information at December 28, 2024 and September 28, 2024 for investment assets and other liabilities measured at fair value on a recurring basis, as well as the carrying amount of certain investments. Fair Value at Reporting Date Using Fair Value Quoted Prices in Significant Significant December 28, 2024 Assets: Money market mutual funds $ 152.1 $ 152.1 $ — $ — U.S. Treasury securities 254.5 254.5 — — Interest rate swaps 9.4 — 9.4 — Foreign currency option contracts 0.4 — 0.4 — Forward foreign currency contracts 9.7 — 9.7 — Total $ 426.1 $ 406.6 $ 19.5 $ — Liabilities: Contingent consideration $ 1.1 $ — $ — $ 1.1 Total $ 1.1 $ — $ — $ 1.1 September 28, 2024 Assets: Money market mutual funds $ 341.7 $ 341.7 $ — $ — U.S. Treasury securities 626.3 626.3 — — Commercial paper 24.9 24.9 — — Interest rate swaps 3.1 — 3.1 — Foreign currency option contracts 0.8 — 0.8 — Total $ 996.8 $ 992.9 $ 3.9 $ — Liabilities: Contingent consideration $ 1.1 $ — $ — $ 1.1 Interest rate swaps 0.2 — 0.2 — Forward foreign currency contracts 12.6 — 12.6 — Total $ 13.9 $ — $ 12.8 $ 1.1 Liabilities Measured and Recorded at Fair Value on a Recurring Basis Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, during the three month periods ended December 28, 2024 and December 30, 2023 were as follows: Three Months Ended December 28, 2024 December 30, 2023 Balance at beginning of period $ 1.1 $ 2.0 Contingent consideration recorded at acquisition — — Fair value adjustments — 1.7 Payments — — Balance at end of period $ 1.1 $ 3.7 Assets Measured and Recorded at Fair Value on a Nonrecurring Basis The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets are comprised of equity investments and long-lived assets, primarily property, plant and equipment, intangible assets and goodwill. During the first quarter of fiscal 2024, the Company recorded a $12.5 million impairment charge for right-of-use lease assets related to the closure of its Mobidiag facilities in Finland and France (see Note 8 for further discussion), reducing the carrying value to zero. In addition, during the first quarter of fiscal 2024, the Company recorded a $4.3 million impairment charge for an in-process research and development project from the Mobidiag acquisition, reducing the carrying value of this asset to $22.4 million. There were no other remeasurements in the three months ended December 28, 2024 and December 30, 2023. Disclosure of Fair Value of Financial Instruments The Company’s financial instruments mainly consist of cash and cash equivalents, United States Treasury securities, commercial paper, accounts receivable, equity investments, interest rate swaps, forward foreign currency contracts, foreign currency option contracts, insurance contracts, accounts payable and debt obligations. The carrying amounts of the Company’s cash and cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s United States Treasury securities, commercial paper, interest rate swaps, forward foreign currency contracts and foreign currency option contracts are recorded at fair value. The carrying amount of the insurance contracts are recorded at the cash surrender value, as required by U.S. GAAP, which approximates fair value. The Company believes the carrying amounts of its equity investments approximate fair value. The Company’s cash and cash equivalents and short and long term investments as of December 28, 2024 were as follows: Valuation Balance Sheet Classification in millions Cost Unrealized Gains Unrealized Losses Fair Value Cash and cash equivalents Investments Cash $ 1,614.0 $ — $ — $ 1,614.0 $ 1,614.0 $ — Money market mutual funds 152.1 — — 152.1 152.1 — U.S. Treasury debt securities 254.1 0.4 — 254.5 16.0 238.5 Total $ 2,020.2 $ 0.4 $ — $ 2,020.6 $ 1,782.1 $ 238.5 The Company classifies its investments in debt securities as available-for-sale and records them at fair value, with changes in fair value reported as a component of accumulated other comprehensive income (loss), which was immaterial for the three months ended December 28, 2024. The Company periodically assesses these securities for potential impairment losses and credit losses. The amount of credit losses, if any, will be determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. There were no impairments and credit losses related to available-for-sale securities for the three months ended December 28, 2024. The Company classifies all highly liquid investments with stated maturities of three months or less from the date of purchase as cash equivalents. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the three months ended December 28, 2024 and December 30, 2023, respectively. There were no sales of available-for-sale securities during the three months ended December 28, 2024. The fair value of the available-for-sale securities by contractual maturity as of December 28, 2024 and September 28, 2024 were as follows: December 28, 2024 September 28, 2024 in millions Fair Value Fair Value Due in three months or less $ 168.1 $ 723.1 Due after three months through one year 190.6 173.4 Due after one year through five years 47.9 96.4 Total available-for-sale securities $ 406.6 $ 992.9 Amounts outstanding under the Company’s 2021 Credit Agreement of $1.2 billion aggregate principal as of December 28, 2024 are subject to variable rates of interest based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The Company’s 4.625% Senior Notes due 2028 (the “2028 Senior Notes”) and 3.250% Senior Notes due 2029 (the “2029 Senior Notes”) had fair values of $387.4 million and $860.9 million, respectively, as of December 28, 2024 based on their trading prices, representing a Level 1 measurement. Refer to Note 9 for the carrying amounts of the various components of the Company’s debt.

Business Combinations

Business Combinations	3 Months Ended
	Dec. 28, 2024
Business Combinations [Abstract]
Business Combinations	Business Combinations Fiscal 2024 Acquisitions Endomag On July 25, 2024, the Company completed the acquisition of Endomagnetics Ltd (“Endomag”) for a purchase price of $313.9 million. Endomag, located in the U.K., develops and sells breast surgery localization and lymphatic tracing technologies. Endomag’s results of operations are reported in the Company's Breast Health reportable segment from the date of acquisition. The purchase price was allocated to Endomag's preliminary tangible and identifiable intangible assets and liabilities based on their preliminary estimated fair values as of July 25, 2024, as set forth below. Cash $ 16.2 Accounts receivable 5.5 Inventory 14.9 Other assets 7.0 Accounts payable and accrued expenses (22.6) Identifiable intangible assets: Developed technology 180.9 Trade names 7.4 Customer relationship 6.5 In-process research and development 3.0 Deferred income taxes, net (43.8) Goodwill 138.9 Purchase Price $ 313.9 In performing the preliminary purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Endomag’s business. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the valuation of acquired assets and liabilities. As part of the preliminary purchase price allocation, the Company determined the identifiable intangible assets are developed technology, trade names, customer relationship and an in-process research and development project. The preliminary fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using a 15.0% rate. The cash flows were based on estimates used to price the transaction, and the discount rate applied was benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The developed technology assets are comprised of know-how, patents and technologies embedded in Endomag’s products and relate to currently marketed products. The developed technology assets comprise the primary product families under the Sentimag, Magseed and Magtrace technology platforms. The preliminary estimate of the weighted average life for the developed technology assets was 11 years, customer relationships was 12 years and trade name assets was 11 years. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. Factors contributing to the recognition of the amount of goodwill were primarily based on anticipated strategic and synergistic benefits that are expected to be realized from the Endomag acquisition. These benefits include expanding the Company’s breast care portfolio and utilizing Breast Health’s sales and regulatory expertise to drive adoption and revenue growth. None of the goodwill is expected to be deductible for income tax purposes.

Strategic Investments

Strategic Investments	3 Months Ended
	Dec. 28, 2024
Equity Method Investments and Joint Ventures [Abstract]
Strategic Investments	Strategic Investments Maverix Medical On November 13, 2023, the Company entered into an agreement with KKR Comet, LLC, an affiliate of KKR & Co. Inc. (“KKR Comet”), to form a legal entity to develop and acquire innovative technologies and commercial operations within the lung cancer space. The new entity, named Maverix Medical LLC (“Maverix”), is managed by Ajax Health. As part of this strategic investment, the Company contributed $24.5 million in return for 45% ownership in the Class A Common units of Maverix, and both the Company and KKR Comet have committed to make additional capital contributions in proportion to the ownership percentages upon meeting certain objectives and as approved by the Maverix board. In accordance with ASC 810, Consolidation, and ASC 323, Investments - Equity Method and Joint Ventures, the Company determined that Maverix is a variable interest entity (“VIE”) however the Company is not the primary beneficiary but does have significant influence. Therefore, this investment has been accounted for under the equity method, which requires the Company to record its proportional share of the investee’s net income (loss). This investment is recorded within Other assets in the Consolidated Balance Sheets and the net investment as of December 28, 2024 was $19.5 million, and the Company’s proportionate share of Maverix’s net loss for the three months ended December 28, 2024 was $1.5 million. During the first quarter of fiscal 2025, the Company received a capital call notice for 13.3% of total committed capital for a total amount of $9.0 million. This capital call was paid in January 2025. Other The Company holds other non-marketable equity securities as part of its strategic investments portfolio. Other non-marketable equity securities are measured at cost, less any impairment, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. In addition, these investments are assessed for indicators of impairment, including adverse changes in technological milestones and financial conditions of the investee. Changes in fair value of these strategic investments are recorded in other income (expense), net in the Consolidated Statements of Income. No such impairments were recorded in the three months ended December 28, 2024 and December 30, 2023. At December 28, 2024 and September 28, 2024, the Company’s investments in equity securities without readily determinable fair values totaled $30.3 million and $25.3 million, respectively, and are included in Other assets on the Consolidated Balance Sheets.

Disposition

Disposition	3 Months Ended
	Dec. 28, 2024
Discontinued Operations and Disposal Groups [Abstract]
Disposition	Disposition Sale of SuperSonic Imagine Ultrasound Imaging Business On September 28, 2023, the Company executed an agreement to sell its SSI ultrasound imaging business to SSH Holdings Limited for a sales price of $1.9 million in cash. Under the terms of the contract, the Company agreed to fund the SSI business with $33.2 million of cash. The sale was completed on October 3, 2023, which was the beginning of the first quarter of fiscal 2024. The Company also agreed to provide certain transition services for up to one year, depending on the nature of the service. The SSI ultrasound imaging asset group met the criteria to be classified as assets held-for-sale in the fourth quarter of fiscal 2023. As a result, the Company recorded a charge of $51.7 million in the fourth quarter of fiscal 2023 to record the asset group to its fair value less costs to sell pursuant to ASC 360, Property, Plant and Equipment-Impairment or Disposal of Long-Lived Assets . The Company concluded that this disposal did not qualify as a discontinued operation as the sale of the SSI ultrasound imaging business was deemed to not be a strategic shift having or that will have a major effect on the Company’s operations and financial results.

Restructuring

Restructuring	3 Months Ended
	Dec. 28, 2024
Restructuring Costs [Abstract]
Restructuring and Related Activities Disclosure	(8) Restructuring During the first quarter of fiscal 2024, the Company further refined its strategy for the Mobidiag business, which is within the Diagnostics reportable segment. The strategy change included the decision to discontinue the manufacture and sale of certain products, closure of its facilities in Finland and France, and to move the development activities and operations to the Company’s San Diego, California location. As such, the Company determined certain fixed assets lives should be shortened and that lease assets were impaired at the affected facilities and recorded accelerated depreciation of $7.2 million and a lease asset impairment charge of $12.5 million. In connection with this plan, the Company finalized its decision to terminate the employees at these locations, totaling 190. The Company initiated discussions with the respective Works Councils at the end of the first quarter of fiscal 2024. In addition, the Company recorded the minimum statutory severance benefit for the employees located in France of $1.8 million pursuant to ASC 712, Compensation Nonretirement Postemployment Benefits (ASC 712), at this time. During the second quarter of fiscal 2024, the Company finalized its negotiations with the respective Works Councils and communicated the termination and related severance benefits to the affected employees. The Company has estimated the total severance charges, including accelerated stock compensation, will be approximately $15.5 million. The majority of the severance benefits will be recorded pursuant to ASC 420, Exit or Disposal Cost Obligations (ASC 420), which requires the severance benefits to be recognized ratably over the service period to obtain such benefits. The employees are ceasing employment in phases. During the three months ended December 28, 2024, the Company recorded severance charges of $1.7 million, and for the year ended September 28, 2024, the Company recorded total severance charges of $11.9 million. This action is expected to be completed in the second half of fiscal 2025. During the first quarter of fiscal 2022, the Company finalized its decision to close its Danbury, Connecticut facility where it manufactured its Breast Health capital equipment products. The manufacturing of the Breast Health capital equipment products and all other support services were transferred to the Company’s Newark, Delaware facility. The transition of manufacturing was completed in the first quarter of fiscal 2025. In addition, research and development, sales and services support and administrative functions were transferred to the Newark, Delaware and Marlborough, Massachusetts facilities. The employees were notified of the closure during the first quarter of fiscal 2022, and the majority of employees located in Danbury were given the option to relocate to the new locations. The Company is recording severance benefits ratably over the required service period pursuant to ASC 420. As a result, the Company recorded severance and benefits charges of $1.1 million and $0.5 million during the three months ended December 28, 2024 and December 30, 2023, respectively. The Company estimates that total severance charges, including retention, relocation and outplacement costs, will be approximately $8.8 million.

Borrowings and Credit Arrangeme

Borrowings and Credit Arrangements	3 Months Ended
	Dec. 28, 2024
Debt Disclosure [Abstract]
Borrowings and Credit Arrangements	Borrowings and Credit Arrangements The Company’s borrowings consisted of the following: December 28, September 28, Current debt obligations, net of debt discount and deferred issuance costs: Term Loan $ 46.8 $ 37.5 Total current debt obligations $ 46.8 $ 37.5 Long-term debt obligations, net of debt discount and issuance costs: Term Loan $ 1,140.2 $ 1,158.7 2028 Senior Notes 397.7 397.6 2029 Senior Notes 941.3 940.8 Total long-term debt obligations $ 2,479.2 $ 2,497.1 Total debt obligations $ 2,526.0 $ 2,534.6 2021 Credit Agreement On September 27, 2021, the Company and certain of its subsidiaries refinanced its then existing term loan and revolving credit facility with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders (the “2018 Credit Agreement”) by entering into a Refinancing Amendment (the “2021 Credit Agreement”). On August 22, 2022, the Company further amended the 2021 Credit Agreement to address the planned phase out of LIBOR by the UK Financial Conduct Authority. Under this amendment, the interest rates applicable to the loans under the 2021 Credit Agreement denominated in U.S. dollars were converted to a variant of the secured overnight financing rate (“SOFR”), as established from time to time by the Federal Reserve Bank of New York, plus a corresponding spread. The 2021 Credit Agreement provided a $1.5 billion secured term loan facility (the “2021 Term Loan”) and a $2.0 billion revolving credit facility (the “2021 Revolver”). As of December 28, 2024, the principal amount outstanding under the 2021 Term Loan was $1.2 billion, and the interest rate was 5.44% per annum. No amounts were outstanding under the 2021 Revolver, and the full amount was available to be borrowed by the Company. Interest expense, weighted average interest rates, and the interest rate at the end of period under the 2021 Credit Agreement were as follows: Three Months Ended December 28, 2024 December 30, 2023 Interest expense $ 18.9 $ 22.6 Weighted average interest rate 5.66 % 6.44 % Interest rate at end of period 5.44 % 6.46 % The Company’s effective interest rate swap agreements, the first of which fixed the SOFR component of the variable interest rate on $1.0 billion of aggregate principal under the 2021 Term Loan at 1.23% and terminated on December 17, 2023, and the second of which fixed the SOFR component of the variable interest rate on $500 million of aggregate principal under the 2021 Term Loan at 3.46% commenced on December 17, 2023 and terminated on December 27, 2024, resulted in the Company receiving $1.6 million and $9.7 million during the three months ended December 28, 2024 and December 30, 2023, respectively. These amounts were recorded as a reduction to interest expense. The 2021 Credit Agreement contains two financial covenants; a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and calculations thereof, are defined in further detail in the 2021 Credit Agreement. As of December 28, 2024, the Company was in compliance with these covenants. 2028 Senior Notes As of December 28, 2024, the Company had 4.625% Senior Notes due 2028 (the “2028 Senior Notes”) outstanding in the aggregate principal balance of $400 million. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company’s domestic subsidiaries and mature on February 1, 2028. 2029 Senior Notes As of December 28, 2024, the Company had 3.250% Senior Notes due 2029 (the “2029 Senior Notes”) outstanding in the aggregate principal balance of $950 million. The 2029 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company’s domestic subsidiaries and mature on February 15, 2029. Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows: Three Months Ended Interest Rate December 28, 2024 December 30, 2023 2028 Senior Notes 4.625 % $ 4.8 $ 4.8 2029 Senior Notes 3.250 % 8.2 8.2 Total $ 13.0 $ 13.0

Trade Receivables and Allowance

Trade Receivables and Allowance for Credit Losses	3 Months Ended
	Dec. 28, 2024
Receivables [Abstract]
Trade Receivables and Allowance for Credit Losses	Trade Receivables and Allowance for Credit Losses The Company applies ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) to its trade receivables and allowances for credit losses, which requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The expected credit losses are developed using an estimated loss rate method that considers historical collection experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The estimated loss rates are applied to trade receivables with similar risk characteristics such as the length of time the balance has been outstanding and the location of the customer. In certain instances, the Company may identify individual trade receivable assets that do not share risk characteristics with other trade receivables, in which case the Company records its expected credit losses on an individual asset basis. For example, potential adverse changes to customer liquidity from new macroeconomic events, such as pandemics and inflation, must be taken into consideration. To date, the Company has not experienced significant customer payment defaults or identified other significant collectability concerns. In connection with assessing credit losses for individual trade receivable assets, the Company considers significant factors relevant to collectability including those specific to the customer such as bankruptcy, length of time an account is outstanding, and the liquidity and financial position of the customer. If a trade receivable asset is evaluated on an individual basis, the Company excludes those assets from the portfolios of trade receivables evaluated on a collective basis. The following is a rollforward of the allowance for credit losses as of December 28, 2024 compared to December 30, 2023: Balance at Credit Loss (Gain) Write-offs, Balance at Three Months Ended: December 28, 2024 $ 41.4 $ (0.3) $ (1.0) $ 40.1 December 30, 2023 $ 38.5 $ 4.9 $ (0.3) $ 43.1

Derivatives

Derivatives	3 Months Ended
	Dec. 28, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives Interest Rate Swaps - Cash Flow Hedge The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate swaps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income (“AOCI”) to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. In fiscal 2019, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023 (during the first quarter of fiscal 2024) to hedge a portion of its variable rate debt. On August 25, 2022, the interest rate swap agreement was restructured (consistent with the 2021 Credit Agreement) to convert the benchmark interest rate from LIBOR to the SOFR rate effective September 23, 2022 with a termination date of December 17, 2023. The Company applied the practical and optional expedients in ASC 848, Reference Rate Reform , in evaluating the impact of modifying the contract, which resulted in no change to the accounting for this derivative contract. The notional amount of this swap was $1.0 billion. The restructured interest rate swap fixed the SOFR component of the variable interest rate on $1.0 billion of the notional amount under the 2021 Credit Agreement at 1.23%. The critical terms of the restructured interest rate swap were designed to mirror the terms of the Company’s SOFR-based borrowings under the 2021 Credit Agreement and therefore were highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on $1.0 billion of principal. Therefore, changes in the fair value of the swap were recorded in AOCI. The contract expired during the first quarter of fiscal 2024. On March 23, 2023, the Company entered into two consecutive interest rate swap contracts with the first contract having an effective date of December 17, 2023 and terminating on December 27, 2024, and the second contract having an effective date of December 27, 2024 and terminating on September 25, 2026. The notional amount of these swaps is $500 million, and the first interest rate swap fixed the SOFR component of the variable interest rate at 3.46%, and the second interest rate swap fixes the SOFR component of the variable interest rate at 2.98%. The critical terms of the interest rate swaps are designed to mirror the terms of the Company’s SOFR-based borrowings under the 2021 Credit Agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the SOFR-based interest payments on $500 million of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of the remaining interest rate swap was an asset position of $9.4 million as of December 28, 2024. Forward Foreign Currency Exchange Contracts and Foreign Currency Option Contracts The Company enters into forward foreign currency exchange contracts and foreign currency option contracts (including collars) to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company’s cash and operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the U.K. Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency contracts are entered into to support transactions made in the ordinary course of business and are not speculative in nature. The Company uses collars and forward contracts as part of its foreign currency hedging strategy to manage the risk associated with fluctuations in foreign currency exchange rates. Collars, which are a combination of a put and call option, limit the range of possible positive or negative returns on an underlying exposure to a specific range. The contracts are generally for periods of one year or less. The Company did not elect hedge accounting for these contracts. As of December 28, 2024, the notional amount was $345.3 million. The change in the fair value of these contracts is recognized directly in earnings as a component of other income (expense), net. Realized and unrealized gains and losses from these contracts, which were the only derivative contracts not designated for hedge accounting, for the three months ended December 28, 2024 and December 30, 2023, respectively, were as follows: Three Months Ended December 28, 2024 December 30, 2023 Amount of realized gain (loss) recognized in income Forward foreign currency contracts $ 0.3 $ 1.3 $ 0.3 $ 1.3 Amount of unrealized gain (loss) recognized in income Forward foreign currency contracts $ 22.4 $ (12.5) Foreign currency option contracts (0.4) — $ 22.0 $ (12.5) Amount of gain (loss) recognized in income Total $ 22.3 $ (11.2) Financial Instrument Presentation The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the balance sheet as of December 28, 2024: Balance Sheet Location December 28, 2024 September 28, 2024 Assets: Derivative instruments designated as a cash flow hedge: Interest rate swap contracts Prepaid expenses and other current assets $ 5.7 $ 3.1 Interest rate swap contracts Other assets 3.7 — $ 9.4 $ 3.1 Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ 9.7 $ — Foreign currency option contracts Prepaid expenses and other current assets 0.4 0.8 $ 10.1 $ 0.8 Liabilities: Derivative instruments designated as a cash flow hedge: Interest rate swap contract Other long-term liabilities $ — $ 0.2 Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses $ — $ 12.6 The following table presents the unrealized gain (loss) recognized in AOCI related to interest rate swaps for the following reporting periods: Three Months Ended December 28, 2024 December 30, 2023 Amount of gain (loss) recognized in other comprehensive income, net of taxes: Interest rate swaps $ 4.9 $ (14.2) Total $ 4.9 $ (14.2)

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Dec. 28, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(12) Commitments and Contingencies Litigation and Related Matters On November 4, 2022, a product liability complaint was filed against the Company in Massachusetts state court by a group of plaintiffs who claim they sustained injuries caused by the BioZorb 3D Bioabsorbable Marker, and additional complaints were subsequently filed alleging similar claims. The BioZorb device is an implantable three-dimensional marker that helps clinicians overcome certain challenges presented by breast conserving cancer surgery (lumpectomy). The complaints allege that the plaintiffs suffered side effects that were not disclosed in the BioZorb instructions for use and make various additional claims related to the design, manufacture and marketing of the device. Complaints have been filed on behalf of approximately 100 plaintiffs, one pending in Massachusetts state court, and the remainder in United States District Court for the District of Massachusetts. Discovery is ongoing. While the Company believes it has valid defenses and plans to vigorously defend its position, litigation can be costly and unpredictable, and at this early stage the Company cannot reasonably assess the outcome of this matter. The Company is a party to various other legal proceedings, claims, governmental and/or regulatory inspections, inquiries and investigations arising out of the ordinary course of its business. The Company believes that except for those matters described above there are no other proceedings, claims, inspections, inquiries or investigations pending against it, the ultimate resolution of which are reasonably likely based upon management’s assessment, to have a material adverse effect on its financial condition or results of operations. It is possible that future results for any particular quarter or annual period may be materially affected by changes in our assumptions or the effectiveness of our strategies relating to these matters. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies

Net Income Per Share

Net Income Per Share	3 Months Ended
	Dec. 28, 2024
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share A reconciliation of basic and diluted share amounts is as follows: Three Months Ended December 28, December 30, Basic weighted average common shares outstanding 230,284 238,627 Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units 1,823 1,587 Diluted weighted average common shares outstanding 232,107 240,214 Weighted-average anti-dilutive shares related to: Outstanding stock options and restricted stock units 829 2,046

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Dec. 28, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income: Three Months Ended December 28, December 30, Cost of revenues $ 3.5 $ 2.8 Research and development 2.5 3.2 Selling and marketing 3.7 3.2 General and administrative 20.4 19.5 $ 30.1 $ 28.7 The Company granted options to purchase 0.5 million and 0.5 million shares of the Company’s common stock during the three months ended December 28, 2024 and December 30, 2023, respectively, with weighted-average exercise prices of $79.38 and $71.93, respectively. There were 4.6 million options outstanding at December 28, 2024 with a weighted-average exercise price of $57.88. The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table: Three Months Ended December 28, December 30, Risk-free interest rate 4.2 % 4.4 % Expected volatility 32.5 % 33.4 % Expected life (in years) 4.8 4.8 Dividend yield — — Weighted average fair value of options granted $ 26.74 $ 24.93 The Company granted 0.8 million and 0.7 million restricted stock units (“RSUs”) during the three months ended December 28, 2024 and December 30, 2023, respectively, with weighted-average grant date fair values of $79.88 and $71.90 per unit, respectively. In addition, the Company granted 0.1 million and 0.1 million performance stock units (“PSUs”) during the three months ended December 28, 2024 and December 30, 2023, respectively, to members of its senior management team, which have a weighted-average grant date fair value of $79.39 and $71.92 per unit, respectively. Each recipient of PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of a three-year performance period, provided that the Company’s defined Return on Invested Capital metrics are achieved. The Company also granted 0.1 million and 0.1 million of free cash flow performance stock units (“FCF PSUs”) based on a three-year cumulative free cash flow measure to members of its senior management team, which had a grant date fair value of $79.39 and $71.92 per unit during the three months ended December 28, 2024 and December 30, 2023, respectively. Each recipient of FCF PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of the three-year measurement period. The PSUs and FCF PSUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense ratably over the required service period based on its estimate of the probable number of shares that will vest upon achieving the measurement criteria. If there is a change in the estimate of the number of shares that are probable of vesting, the Company will cumulatively adjust compensation expense in the period that the change in estimate is made. The Company also granted 0.1 million and 0.1 million market stock units (“MSUs”) to members of its senior management team during the three months ended December 28, 2024 and December 30, 2023, respectively. Each recipient of MSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of a three-year performance period based upon achieving a certain total shareholder return relative to a defined peer group. The MSUs were valued at $87.41 and $88.06 per share using the Monte Carlo simulation model in fiscal 2025 and 2024, respectively. The MSUs cliff-vest three years from the date of grant, and the Company recognizes compensation expense for the MSUs ratably over the service period. At December 28, 2024, there was 1.8 million in aggregate unvested RSUs, PSUs, FCF PSUs and MSUs outstanding. At December 28, 2024, there was $17.8 million and $89.1 million of unrecognized compensation expense related to stock options and stock units (comprised of RSUs, PSUs, FCF PSUs and MSUs), respectively, to be recognized over a weighted-average period of 2.4 and 2.0 years, respectively.

Other Balance Sheet Information

Other Balance Sheet Information	3 Months Ended
	Dec. 28, 2024
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Information	Other Balance Sheet Information December 28, September 28, Inventories Raw materials $ 269.4 $ 251.4 Work-in-process 60.6 62.0 Finished goods 377.1 366.4 $ 707.1 $ 679.8 Property, plant and equipment Equipment $ 383.2 $ 378.1 Equipment under customer usage agreements 521.8 523.1 Building and improvements 248.3 247.1 Leasehold improvements 44.4 44.0 Land 40.7 40.8 Furniture and fixtures 25.6 24.6 Finance lease right-of-use asset 8.2 8.8 $ 1,272.2 $ 1,266.5 Less – accumulated depreciation and amortization (735.0) (728.7) $ 537.2 $ 537.8

Business Segments and Geographi

Business Segments and Geographic Information	3 Months Ended
	Dec. 28, 2024
Segment Reporting [Abstract]
Business Segments and Geographic Information	Business Segments and Geographic Information The Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges (such as intangible asset amortization expense, and goodwill and intangible asset impairment charges), transaction and integration expenses for acquisitions, restructuring, consolidation and divestiture charges, litigation charges, and other one-time or unusual items. Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three months ended December 28, 2024 and December 30, 2023. Segment information is as follows: Three Months Ended December 28, December 30, Total revenues: Diagnostics $ 470.6 $ 447.8 Breast Health 369.1 377.7 GYN Surgical 166.3 162.2 Skeletal Health 15.8 25.4 $ 1,021.8 $ 1,013.1 Income (loss) from operations: Diagnostics $ 118.9 $ 49.4 Breast Health 67.5 102.2 GYN Surgical 46.6 43.2 Skeletal Health (3.2) 3.4 $ 229.8 $ 198.2 Depreciation and amortization: Diagnostics $ 48.6 $ 65.9 Breast Health 13.2 10.3 GYN Surgical 12.0 12.0 Skeletal Health 0.2 0.2 $ 74.0 $ 88.4 Capital expenditures: Diagnostics $ 17.8 $ 24.2 Breast Health 8.9 9.3 GYN Surgical 3.7 4.2 Skeletal Health — 0.1 Corporate 1.2 0.2 $ 31.6 $ 38.0 December 28, September 28, Identifiable assets: Diagnostics $ 2,412.9 $ 2,431.3 Breast Health 1,556.8 1,588.9 GYN Surgical 1,429.0 1,419.9 Skeletal Health 44.7 48.3 Corporate 3,285.3 3,667.6 $ 8,728.7 $ 9,156.0 The Company had no customers that represented greater than 10% of consolidated revenues during the three months ended December 28, 2024 and December 30, 2023. The Company operates in the following major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from the United Kingdom, Germany, France, Spain, Italy and the Netherlands. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of World” designation includes Canada, Latin America and the Middle East. Revenues by geography as a percentage of total revenues were as follows: Three Months Ended December 28, December 30, United States 74.2 % 74.4 % Europe 14.6 % 14.1 % Asia-Pacific 5.9 % 6.3 % Rest of World 5.3 % 5.2 % 100.0 % 100.0 %

Income Taxes

Income Taxes	3 Months Ended
	Dec. 28, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes In accordance with ASC 740, Income Taxes , each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period. For the three months ended December 28, 2024, the Company recorded income tax expense of $46.5 million resulting in an effective tax rate of 18.8%. The effective tax rate for the three months ended December 28, 2024 was lower than the U.S. statutory tax rate primarily due to the U.S. deduction for foreign derived intangible income, the geographic mix of income earned by the Company’s international subsidiaries, which are generally taxed at rates lower than the U.S. statutory tax rate, and federal and state tax credits, partially offset by U.S. tax on foreign earnings. For the three months ended December 30, 2023, the Company recorded an income tax benefit of $55.2 million resulting in an effective tax rate of (28.9)%. The effective tax rate for the three months ended December 30, 2023 was lower than the U.S. statutory tax rate primarily due to a $107.2 million discrete tax benefit related to a worthless stock deduction on the investment in one of the Company’s international subsidiaries. Non-Income Tax Matters The Company is subject to tax examinations for value added, sales-based, payroll and other non-income tax items. A number of these examinations are ongoing in various jurisdictions. The Company takes certain non-income tax positions in the jurisdictions in which it operates and records loss contingencies pursuant to ASC 450. Such amounts were not material for any of the periods presented. In the normal course of business, the Company's positions and conclusions related to its non-income tax positions could be challenged, resulting in assessments by governmental authorities. While the Company believes estimated losses previously recorded are reasonable, certain audits are still ongoing and additional charges could be recorded in the future.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	3 Months Ended
	Dec. 28, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	Intangible Assets Intangible assets consisted of the following: Description As of December 28, 2024 As of September 28, 2024 Gross Accumulated Gross Accumulated Acquired intangible assets: Developed technology $ 4,562.7 $ 3,877.3 $ 4,567.0 $ 3,834.0 In-process research and development 24.9 — 25.1 — Customer relationships 607.7 570.2 609.7 569.8 Trade names 259.6 225.5 260.3 224.5 Total acquired intangible assets $ 5,454.9 $ 4,673.0 $ 5,462.1 $ 4,628.3 Internal-use software 26.0 20.8 25.7 20.5 Capitalized software embedded in products 31.1 24.9 30.2 24.6 Total intangible assets $ 5,512.0 $ 4,718.7 $ 5,518.0 $ 4,673.4 The estimated remaining amortization expense of the Company’s acquired intangible assets as of December 28, 2024 for each of the five succeeding fiscal years was as follows: Remainder of Fiscal 2025 $ 148.1 Fiscal 2026 $ 169.0 Fiscal 2027 $ 81.9 Fiscal 2028 $ 78.8 Fiscal 2029 $ 73.2 During the first quarter of fiscal 2024, the Company assessed its in-process research and development intangible asset from its Mobidiag acquisition for impairment. The Company determined the fair value of this indefinite-lived asset utilizing the discounted cash flow model and recorded a $4.3 million impairment charge, reducing the fair value of this asset to $22.4 million. The reduction in the fair value of this asset was primarily due to a reduction in forecasted revenues and a delay in the timing of completing the project. In addition, the Company determined that the useful life of the customer relationship and trade name intangible assets from its Mobidiag acquisition should be shortened and recorded accelerated amortization expense of $7.3 million to bring the net carrying values to zero.

Product Warranties

Product Warranties	3 Months Ended
	Dec. 28, 2024
Guarantees [Abstract]
Product Warranties	Product Warranties Product warranty activity was as follows: Balance at Provisions Settlements/ Balance at Three Months Ended: December 28, 2024 $ 9.9 $ 2.4 $ (2.3) $ 10.0 December 30, 2023 $ 8.3 $ 2.9 $ (2.1) $ 9.1

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	3 Months Ended
	Dec. 28, 2024
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) The following tables summarize the changes in accumulated balances of other comprehensive income (loss) for the periods presented: Three Months Ended December 28, 2024 Foreign Currency Translation Available-For-Sale Debt Securities Hedged Interest Rate Swaps Total Beginning Balance $ (114.9) $ 1.6 $ 1.8 $ (111.5) Other comprehensive income (loss) before reclassifications (54.8) (1.3) 4.9 (51.2) Ending Balance $ (169.7) $ 0.3 $ 6.7 $ (162.7) Three Months Ended December 30, 2023 Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Beginning Balance $ (168.0) $ 0.3 $ 20.1 $ (147.6) Other comprehensive income (loss) before reclassifications 43.0 — (14.2) 28.8 Ending Balance $ (125.0) $ 0.3 $ 5.9 $ (118.8)

Share Repurchase

Share Repurchase	3 Months Ended
	Dec. 28, 2024
Equity [Abstract]
Share Repurchase	Share Repurchase On September 22, 2022, the Board of Directors authorized a stock repurchase program, with a five-year term, to repurchase up to $1.0 billion of the Company’s outstanding common stock, effective as of the close of trading September 23, 2022. This repurchase program replaced the previous $1.0 billion authorization. During the three months ended December 28, 2024, the Company repurchased 2.4 million shares of its common stock under this authorization for total consideration of $190.3 million. As of December 28, 2024, no amounts remained available under this authorization. On September 12, 2024, the Board of Directors authorized a new stock repurchase program, with a five-year term, to repurchase up to $1.5 billion of the Company’s outstanding stock. This new stock repurchase authorization was in addition to the Company’s prior stock repurchase authorization. Exclusive of shares repurchased pursuant to the accelerated share repurchase agreement described below, during the three months ended December 28, 2024, the Company repurchased 1.1 million shares of its common stock under this authorization for total consideration of $77.0 million. As of December 28, 2024, $1.17 billion remained unused under this authorization. Subsequent to December 28, 2024, the Company repurchased 1.4 million shares for a total consideration of $95.1 million On November 19, 2024, the Company executed an accelerated share repurchase (“ASR”) agreement with JPMorgan Chase & Co., (“JP Morgan”) pursuant to its existing authorizations and pursuant to which the Company agreed to repurchase $250.0 million of the Company’s common stock. In connection with the launch of the ASR, on November 20, 2024, the Company paid JP Morgan an aggregate of $250.0 million and received approximately 2.5 million shares of the Company’s common stock, representing 80% of the transaction value based on the Company’s closing share price on November 18, 2024. On December 23, 2024, the ASR agreement was completed, and the Company received an additional 0.8 million shares for the final settlement. This final settlement was based on the total transaction value and the volume-weighted average share price of the Company’s common stock during the term of the agreement.

New Accounting Pronouncements

New Accounting Pronouncements	3 Months Ended
	Dec. 28, 2024
Accounting Policies [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures . The guidance requires entities to provide enhanced disclosures about significant segment expenses. For entities that have adopted the amendments in Update 2023-07, the updated guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and is applicable to the Company for its annual report on Form 10-K for fiscal 2025. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-07 on its consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) Improvements to Income Tax Disclosures . The FASB issued this update to enhance income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2024, and is applicable to the Company in fiscal 2026. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its consolidated financial position and results of operations. In March 2024, the SEC issued its final climate disclosure rule, which requires the disclosure of Scope 1 and Scope 2 greenhouse gas emissions and other climate-related topics in annual reports and registration statements, when material. Disclosure requirements were to begin phasing in for fiscal years beginning on or after January 1, 2025, however on April 4, 2024, the SEC issued an order staying the rule pending the completion of an ongoing judicial review. The Company is monitoring SEC developments and evaluating the impact of the new rule to its financial statements. In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income (Topic 220) Expense Disaggregation Disclosures. This update is intended to improve the disclosures related to expenses and provide investors more detailed information about certain types of expenses. For entities that have adopted the amendments in Update 2024-03, the updated guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, and is applicable to the Company beginning with its annual report on Form 10-K for fiscal 2028. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2024-03 on its consolidated financial statements.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Sep. 28, 2024	Jun. 29, 2024	Mar. 30, 2024	Dec. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss) Attributable to Parent	$ 201	$ 178.6	$ 194.5	$ 169.9	$ 246.5

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 28, 2024 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Amy Wendell [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	During the first quarter of fiscal 2025, Amy Wendell, Lead Independent Director of our Board of Directors, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act on December 2, 2024 to sell up to 1,500 shares of our common stock (following the exercise of options) between March 3, 2025 and November 21, 2025, the date this plan expires. The trading plan will cease upon the earlier of November 21, 2025 or the sale of all shares subject to the trading plan.
Name	Amy Wendell
Title	Lead Independent Director
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	December 2, 2024
Expiration Date	November 21, 2025
Arrangement Duration	354 days
Aggregate Available	1,500
Stephen MacMillan [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	During the first quarter of fiscal 2025, Stephen MacMillan, Chairman, President and Chief Executive Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) under the Exchange Act on December 12, 2024 to sell up to 138,358 shares of our common stock (following the exercise of options) between March 14, 2025 and November 6, 2025, the date this plan expires. The trading plan will cease upon the earlier of November 6, 2025 or the sale of all shares subject to the trading plan.
Name	Stephen MacMillan
Title	Chairman, President and Chief Executive Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	December 12, 2024
Expiration Date	November 6, 2025
Arrangement Duration	329 days
Aggregate Available	138,358

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Dec. 28, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The unaudited consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”) for annual financial statements. These unaudited financial statements should be read in conjunction with the consolidated financial statements and related notes for the fiscal year ended September 28, 2024 included in the Company’s annual report on Form 10-K filed with the SEC on November 27, 2024. In the opinion of management, the unaudited financial statements and notes contain all adjustments (consisting of normal recurring accruals and all other necessary adjustments) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented.
Principal of Consolidation	The unaudited consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three months ended December 28, 2024 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 27, 2025.
Subsequent Events Consideration	Subsequent Events Consideration The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events, except as described below, affecting the unaudited consolidated financial statements as of and for the three months ended December 28, 2024. On January 2, 2025, the Company completed the acquisition of Gynesonics, Inc. (“Gynesonics”) for a purchase price of approximately $350.0 million, subject to working capital and other customary adjustments. Gynesonics, located in Redwood City, California, develops a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. Gynesonics will be included in the GYN Surgical reportable segment.

Revenue from Contract with Cust

Revenue from Contract with Customer (Policies)	3 Months Ended
	Dec. 28, 2024
Revenue from Contract with Customer [Abstract]
Revenue	(2) Revenue The Company accounts for revenue pursuant to ASC 606, Revenue from Contracts with Customers (ASC 606), and generates revenue from the sale of its products, primarily medical imaging systems and related components and software, diagnostic tests and assays and surgical disposable products, and related services, which are primarily support and maintenance services on its medical imaging systems, and to a lesser extent installation, training and repairs. In addition, the Company generates service revenue from performing laboratory testing services through its Biotheranostics CLIA laboratory, which is included in its Molecular Diagnostics business. The Company’s products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors and resellers. Revenue is recorded net of sales tax. The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis: Three Months Ended December 28, 2024 Business ( in millions ) United States International Total Diagnostics: Cytology & Perinatal $ 76.0 $ 49.4 $ 125.4 Molecular Diagnostics 262.6 78.5 341.1 Blood Screening 4.1 — 4.1 Total $ 342.7 $ 127.9 $ 470.6 Breast Health: Breast Imaging $ 215.7 $ 65.9 $ 281.6 Interventional Breast Solutions 66.3 21.2 87.5 Total $ 282.0 $ 87.1 $ 369.1 GYN Surgical $ 121.9 $ 44.4 $ 166.3 Skeletal Health $ 11.3 $ 4.5 $ 15.8 $ 757.9 $ 263.9 $ 1,021.8 Three Months Ended December 30, 2023 Business (in millions) United States International Total Diagnostics: Cytology & Perinatal $ 69.8 $ 50.2 $ 120.0 Molecular Diagnostics 247.6 72.2 319.8 Blood Screening 8.0 — 8.0 Total $ 325.4 $ 122.4 $ 447.8 Breast Health: Breast Imaging $ 228.4 $ 73.0 $ 301.4 Interventional Breast Solutions 61.1 15.2 76.3 Total $ 289.5 $ 88.2 $ 377.7 GYN Surgical $ 125.1 $ 37.1 $ 162.2 Skeletal Health $ 13.7 $ 11.7 $ 25.4 $ 753.7 $ 259.4 $ 1,013.1 Three Months Ended Geographic Regions ( in millions ) December 28, 2024 December 30, 2023 United States $ 757.9 $ 753.7 Europe 148.9 142.8 Asia-Pacific 59.8 63.8 Rest of World 55.2 52.8 $ 1,021.8 $ 1,013.1 The following table provides revenue recognized by source: Three Months Ended Revenue by type (in millions) December 28, 2024 December 30, 2023 Disposables $ 663.7 $ 628.9 Capital equipment, components and software 154.2 199.2 Service 198.6 178.8 Other 5.3 6.2 $ 1,021.8 $ 1,013.1 The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Company’s products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the point in time when the customer obtains the use of and substantially all of the remaining benefits of the product. As such, the Company’s performance obligation related to product sales is satisfied at a point in time. Revenue from support and maintenance contracts, extended warranty, and professional services for installation, training and repairs is recognized over time based on the period contracted or as the services are performed as these methods represent a faithful depiction of the transfer of goods and services. The Company recognizes a receivable when it has an unconditional right to payment, which represents the amount the Company expects to collect in a transaction and is most often equal to the transaction price in the contract. Payment terms are typically 30 days in the U.S. but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within costs of product revenue when the corresponding revenue is recognized. The Company also places instruments (or equipment) at customer sites but retains title to the instrument. The customer has the right to use the instrument for a period of time, and the Company recovers the cost of providing the instrument through the sales of disposables, namely tests and assays in Diagnostics and handpieces in GYN Surgical. These types of agreements include an embedded lease, which is generally an operating lease, for the right to use an instrument and no instrument revenue is recognized at the time of instrument delivery. The Company recognizes a portion of the revenue allocated to the embedded lease concurrent with the sale of disposables over the term of the agreement. Revenue from laboratory testing services, which is generated by the Company’s Biotheranostics business, is recognized based upon contracted amounts with payors and historical cash collection experience for the same test or same payor group. Revenue is recognized once the laboratory services have been performed, the results have been delivered to the ordering physician, the payor has been identified, and insurance has been verified. The estimated timeframes for cash collection are three months for Medicare payors, six months for Medicare Advantage payors, and nine months for commercial payors. Generally, the contracts for capital equipment include multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price to each performance obligation using its best estimate of the standalone selling price of each distinct good or service in the contract. The Company determines its best estimate of standalone selling price using average selling prices over 3- to 12-month periods of data depending on the products or nature of the services coupled with current market considerations. If the product or service does not have a history of sales or if sales volume is not sufficient, the Company relies on prices set by its pricing committees or applicable marketing department adjusted for expected discounts. Variable Consideration The Company exercises judgment in estimating variable consideration, which includes volume discounts, sales rebates, product returns and other adjustments. These amounts are recorded as a reduction to revenue and classified as a current liability. The Company bases its estimates for volume discounts and sales rebates on historical information to the extent it is reasonable to be used as a predictive tool of expected future rebates. To the extent the transaction price includes variable consideration, the Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer contracts. The Company’s contracts for the sale of capital equipment and related components, and assays and tests typically do not provide the right to return product, however, its contracts for the sale of its GYN Surgical and Interventional Breast Solutions surgical handpieces provide for a right of return for a limited period of time. In general, estimates of variable consideration and constraints are not material to the Company’s financial statements. Remaining Performance Obligations As of December 28, 2024, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately $863.7 million. These remaining performance obligations primarily relate to support and maintenance obligations and extended warranty in the Company’s Breast Health and Skeletal Health reportable segments. The Company expects to recognize approximately 38% of this amount as revenue in fiscal 2025, 33% in fiscal 2026, 17% in fiscal 2027, 8% in fiscal 2028, and 4% thereafter. As permitted, the Company does not include remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above. Contract Assets and Liabilities The Company discloses accounts receivable separately in the Consolidated Balance Sheets at their net realizable value. Contract assets primarily relate to the Company’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial. Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations within the Company’s Breast Health and Skeletal Health reportable segments. Contract liabilities are classified as other current liabilities and other long-term liabilities in the Consolidated Balance Sheets. The Company recognized revenue of $70.0 million and $64.4 million in the three months ended December 28, 2024 and December 30, 2023, respectively, that was included in the contract liability at September 28, 2024 and September 30, 2023, respectively. Practical Expedients The Company applies a practical expedient to expense costs to obtain a contract with a customer as incurred when the amortization period would have been one year or less. These costs solely comprise sales commissions and typically the commissions are incurred at the time of shipment of product and upon billings for support and maintenance contracts.

New Accounting Pronouncements (

New Accounting Pronouncements (Policies)	3 Months Ended
	Dec. 28, 2024
Accounting Policies [Abstract]
New Accounting Pronouncements	In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures . The guidance requires entities to provide enhanced disclosures about significant segment expenses. For entities that have adopted the amendments in Update 2023-07, the updated guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and is applicable to the Company for its annual report on Form 10-K for fiscal 2025. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-07 on its consolidated financial statements. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) Improvements to Income Tax Disclosures . The FASB issued this update to enhance income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2024, and is applicable to the Company in fiscal 2026. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its consolidated financial position and results of operations. In March 2024, the SEC issued its final climate disclosure rule, which requires the disclosure of Scope 1 and Scope 2 greenhouse gas emissions and other climate-related topics in annual reports and registration statements, when material. Disclosure requirements were to begin phasing in for fiscal years beginning on or after January 1, 2025, however on April 4, 2024, the SEC issued an order staying the rule pending the completion of an ongoing judicial review. The Company is monitoring SEC developments and evaluating the impact of the new rule to its financial statements. In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income (Topic 220) Expense Disaggregation Disclosures. This update is intended to improve the disclosures related to expenses and provide investors more detailed information about certain types of expenses. For entities that have adopted the amendments in Update 2024-03, the updated guidance is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, and is applicable to the Company beginning with its annual report on Form 10-K for fiscal 2028. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2024-03 on its consolidated financial statements.

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Dec. 28, 2024
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis: Three Months Ended December 28, 2024 Business ( in millions ) United States International Total Diagnostics: Cytology & Perinatal $ 76.0 $ 49.4 $ 125.4 Molecular Diagnostics 262.6 78.5 341.1 Blood Screening 4.1 — 4.1 Total $ 342.7 $ 127.9 $ 470.6 Breast Health: Breast Imaging $ 215.7 $ 65.9 $ 281.6 Interventional Breast Solutions 66.3 21.2 87.5 Total $ 282.0 $ 87.1 $ 369.1 GYN Surgical $ 121.9 $ 44.4 $ 166.3 Skeletal Health $ 11.3 $ 4.5 $ 15.8 $ 757.9 $ 263.9 $ 1,021.8 Three Months Ended December 30, 2023 Business (in millions) United States International Total Diagnostics: Cytology & Perinatal $ 69.8 $ 50.2 $ 120.0 Molecular Diagnostics 247.6 72.2 319.8 Blood Screening 8.0 — 8.0 Total $ 325.4 $ 122.4 $ 447.8 Breast Health: Breast Imaging $ 228.4 $ 73.0 $ 301.4 Interventional Breast Solutions 61.1 15.2 76.3 Total $ 289.5 $ 88.2 $ 377.7 GYN Surgical $ 125.1 $ 37.1 $ 162.2 Skeletal Health $ 13.7 $ 11.7 $ 25.4 $ 753.7 $ 259.4 $ 1,013.1 Three Months Ended Geographic Regions ( in millions ) December 28, 2024 December 30, 2023 United States $ 757.9 $ 753.7 Europe 148.9 142.8 Asia-Pacific 59.8 63.8 Rest of World 55.2 52.8 $ 1,021.8 $ 1,013.1 The following table provides revenue recognized by source: Three Months Ended Revenue by type (in millions) December 28, 2024 December 30, 2023 Disposables $ 663.7 $ 628.9 Capital equipment, components and software 154.2 199.2 Service 198.6 178.8 Other 5.3 6.2 $ 1,021.8 $ 1,013.1

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Dec. 28, 2024
Fair Value Disclosures [Abstract]
Fair Value Assets and Liabilities Measured on Recurring Basis	Fair Value at Reporting Date Using Fair Value Quoted Prices in Significant Significant December 28, 2024 Assets: Money market mutual funds $ 152.1 $ 152.1 $ — $ — U.S. Treasury securities 254.5 254.5 — — Interest rate swaps 9.4 — 9.4 — Foreign currency option contracts 0.4 — 0.4 — Forward foreign currency contracts 9.7 — 9.7 — Total $ 426.1 $ 406.6 $ 19.5 $ — Liabilities: Contingent consideration $ 1.1 $ — $ — $ 1.1 Total $ 1.1 $ — $ — $ 1.1 September 28, 2024 Assets: Money market mutual funds $ 341.7 $ 341.7 $ — $ — U.S. Treasury securities 626.3 626.3 — — Commercial paper 24.9 24.9 — — Interest rate swaps 3.1 — 3.1 — Foreign currency option contracts 0.8 — 0.8 — Total $ 996.8 $ 992.9 $ 3.9 $ — Liabilities: Contingent consideration $ 1.1 $ — $ — $ 1.1 Interest rate swaps 0.2 — 0.2 — Forward foreign currency contracts 12.6 — 12.6 — Total $ 13.9 $ — $ 12.8 $ 1.1 Liabilities Measured and Recorded at Fair Value on a Recurring Basis Changes in the fair value of recurring fair value measurements using significant unobservable inputs (Level 3), which solely consisted of contingent consideration liabilities, during the three month periods ended December 28, 2024 and December 30, 2023 were as follows: Three Months Ended December 28, 2024 December 30, 2023 Balance at beginning of period $ 1.1 $ 2.0 Contingent consideration recorded at acquisition — — Fair value adjustments — 1.7 Payments — — Balance at end of period $ 1.1 $ 3.7
Schedule of Cash and Cash Equivalents	The Company’s cash and cash equivalents and short and long term investments as of December 28, 2024 were as follows: Valuation Balance Sheet Classification in millions Cost Unrealized Gains Unrealized Losses Fair Value Cash and cash equivalents Investments Cash $ 1,614.0 $ — $ — $ 1,614.0 $ 1,614.0 $ — Money market mutual funds 152.1 — — 152.1 152.1 — U.S. Treasury debt securities 254.1 0.4 — 254.5 16.0 238.5 Total $ 2,020.2 $ 0.4 $ — $ 2,020.6 $ 1,782.1 $ 238.5
Debt Securities, Available-for-Sale	The fair value of the available-for-sale securities by contractual maturity as of December 28, 2024 and September 28, 2024 were as follows: December 28, 2024 September 28, 2024 in millions Fair Value Fair Value Due in three months or less $ 168.1 $ 723.1 Due after three months through one year 190.6 173.4 Due after one year through five years 47.9 96.4 Total available-for-sale securities $ 406.6 $ 992.9

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Dec. 28, 2024
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The purchase price was allocated to Endomag's preliminary tangible and identifiable intangible assets and liabilities based on their preliminary estimated fair values as of July 25, 2024, as set forth below. Cash $ 16.2 Accounts receivable 5.5 Inventory 14.9 Other assets 7.0 Accounts payable and accrued expenses (22.6) Identifiable intangible assets: Developed technology 180.9 Trade names 7.4 Customer relationship 6.5 In-process research and development 3.0 Deferred income taxes, net (43.8) Goodwill 138.9 Purchase Price $ 313.9

Borrowings and Credit Arrange_2

Borrowings and Credit Arrangements (Tables)	3 Months Ended
	Dec. 28, 2024
Debt Disclosure [Abstract]
Company's Borrowings	The Company’s borrowings consisted of the following: December 28, September 28, Current debt obligations, net of debt discount and deferred issuance costs: Term Loan $ 46.8 $ 37.5 Total current debt obligations $ 46.8 $ 37.5 Long-term debt obligations, net of debt discount and issuance costs: Term Loan $ 1,140.2 $ 1,158.7 2028 Senior Notes 397.7 397.6 2029 Senior Notes 941.3 940.8 Total long-term debt obligations $ 2,479.2 $ 2,497.1 Total debt obligations $ 2,526.0 $ 2,534.6
Schedule Of Interest Expense Under Credit Agreement	Interest expense, weighted average interest rates, and the interest rate at the end of period under the 2021 Credit Agreement were as follows: Three Months Ended December 28, 2024 December 30, 2023 Interest expense $ 18.9 $ 22.6 Weighted average interest rate 5.66 % 6.44 % Interest rate at end of period 5.44 % 6.46 %
Schedule of Interest Expense Under Convertible Notes	Interest expense for the 2029 Senior Notes and 2028 Senior Notes was as follows: Three Months Ended Interest Rate December 28, 2024 December 30, 2023 2028 Senior Notes 4.625 % $ 4.8 $ 4.8 2029 Senior Notes 3.250 % 8.2 8.2 Total $ 13.0 $ 13.0

Trade Receivables and Allowan_2

Trade Receivables and Allowance for Credit Losses (Tables)	3 Months Ended
	Dec. 28, 2024
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable	The following is a rollforward of the allowance for credit losses as of December 28, 2024 compared to December 30, 2023: Balance at Credit Loss (Gain) Write-offs, Balance at Three Months Ended: December 28, 2024 $ 41.4 $ (0.3) $ (1.0) $ 40.1 December 30, 2023 $ 38.5 $ 4.9 $ (0.3) $ 43.1

Derivatives (Tables)

Derivatives (Tables)	3 Months Ended
	Dec. 28, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments, Gain (Loss)	Three Months Ended December 28, 2024 December 30, 2023 Amount of realized gain (loss) recognized in income Forward foreign currency contracts $ 0.3 $ 1.3 $ 0.3 $ 1.3 Amount of unrealized gain (loss) recognized in income Forward foreign currency contracts $ 22.4 $ (12.5) Foreign currency option contracts (0.4) — $ 22.0 $ (12.5) Amount of gain (loss) recognized in income Total $ 22.3 $ (11.2)
Schedule of Derivative Assets at Fair Value	The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the balance sheet as of December 28, 2024: Balance Sheet Location December 28, 2024 September 28, 2024 Assets: Derivative instruments designated as a cash flow hedge: Interest rate swap contracts Prepaid expenses and other current assets $ 5.7 $ 3.1 Interest rate swap contracts Other assets 3.7 — $ 9.4 $ 3.1 Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ 9.7 $ — Foreign currency option contracts Prepaid expenses and other current assets 0.4 0.8 $ 10.1 $ 0.8 Liabilities: Derivative instruments designated as a cash flow hedge: Interest rate swap contract Other long-term liabilities $ — $ 0.2 Derivatives not designated as hedging instruments: Forward foreign currency contracts Accrued expenses $ — $ 12.6
Schedule of Unrealized Loss Recognized in AOCI	The following table presents the unrealized gain (loss) recognized in AOCI related to interest rate swaps for the following reporting periods: Three Months Ended December 28, 2024 December 30, 2023 Amount of gain (loss) recognized in other comprehensive income, net of taxes: Interest rate swaps $ 4.9 $ (14.2) Total $ 4.9 $ (14.2)

Net Income Per Share (Tables)

Net Income Per Share (Tables)	3 Months Ended
	Dec. 28, 2024
Earnings Per Share [Abstract]
Reconciliation of Basic and Diluted Share Amounts	A reconciliation of basic and diluted share amounts is as follows: Three Months Ended December 28, December 30, Basic weighted average common shares outstanding 230,284 238,627 Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units 1,823 1,587 Diluted weighted average common shares outstanding 232,107 240,214 Weighted-average anti-dilutive shares related to: Outstanding stock options and restricted stock units 829 2,046

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Dec. 28, 2024
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation Expense in Consolidated Statements of Operations	The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income: Three Months Ended December 28, December 30, Cost of revenues $ 3.5 $ 2.8 Research and development 2.5 3.2 Selling and marketing 3.7 3.2 General and administrative 20.4 19.5 $ 30.1 $ 28.7
Weighted-Average Assumptions Utilized to Value Stock Options	The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table: Three Months Ended December 28, December 30, Risk-free interest rate 4.2 % 4.4 % Expected volatility 32.5 % 33.4 % Expected life (in years) 4.8 4.8 Dividend yield — — Weighted average fair value of options granted $ 26.74 $ 24.93

Other Balance Sheet Informati_2

Other Balance Sheet Information (Tables)	3 Months Ended
	Dec. 28, 2024
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Information of Inventories	December 28, September 28, Inventories Raw materials $ 269.4 $ 251.4 Work-in-process 60.6 62.0 Finished goods 377.1 366.4 $ 707.1 $ 679.8
Other Balance Sheet Information of Property, Plant and Equipment	Property, plant and equipment Equipment $ 383.2 $ 378.1 Equipment under customer usage agreements 521.8 523.1 Building and improvements 248.3 247.1 Leasehold improvements 44.4 44.0 Land 40.7 40.8 Furniture and fixtures 25.6 24.6 Finance lease right-of-use asset 8.2 8.8 $ 1,272.2 $ 1,266.5 Less – accumulated depreciation and amortization (735.0) (728.7) $ 537.2 $ 537.8

Business Segments and Geograp_2

Business Segments and Geographic Information (Tables)	3 Months Ended
	Dec. 28, 2024
Segment Reporting [Abstract]
Segment Information	egment information is as follows: Three Months Ended December 28, December 30, Total revenues: Diagnostics $ 470.6 $ 447.8 Breast Health 369.1 377.7 GYN Surgical 166.3 162.2 Skeletal Health 15.8 25.4 $ 1,021.8 $ 1,013.1 Income (loss) from operations: Diagnostics $ 118.9 $ 49.4 Breast Health 67.5 102.2 GYN Surgical 46.6 43.2 Skeletal Health (3.2) 3.4 $ 229.8 $ 198.2 Depreciation and amortization: Diagnostics $ 48.6 $ 65.9 Breast Health 13.2 10.3 GYN Surgical 12.0 12.0 Skeletal Health 0.2 0.2 $ 74.0 $ 88.4 Capital expenditures: Diagnostics $ 17.8 $ 24.2 Breast Health 8.9 9.3 GYN Surgical 3.7 4.2 Skeletal Health — 0.1 Corporate 1.2 0.2 $ 31.6 $ 38.0 December 28, September 28, Identifiable assets: Diagnostics $ 2,412.9 $ 2,431.3 Breast Health 1,556.8 1,588.9 GYN Surgical 1,429.0 1,419.9 Skeletal Health 44.7 48.3 Corporate 3,285.3 3,667.6 $ 8,728.7 $ 9,156.0
Revenues by Geography	Revenues by geography as a percentage of total revenues were as follows: Three Months Ended December 28, December 30, United States 74.2 % 74.4 % Europe 14.6 % 14.1 % Asia-Pacific 5.9 % 6.3 % Rest of World 5.3 % 5.2 % 100.0 % 100.0 %

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	3 Months Ended
	Dec. 28, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following: Description As of December 28, 2024 As of September 28, 2024 Gross Accumulated Gross Accumulated Acquired intangible assets: Developed technology $ 4,562.7 $ 3,877.3 $ 4,567.0 $ 3,834.0 In-process research and development 24.9 — 25.1 — Customer relationships 607.7 570.2 609.7 569.8 Trade names 259.6 225.5 260.3 224.5 Total acquired intangible assets $ 5,454.9 $ 4,673.0 $ 5,462.1 $ 4,628.3 Internal-use software 26.0 20.8 25.7 20.5 Capitalized software embedded in products 31.1 24.9 30.2 24.6 Total intangible assets $ 5,512.0 $ 4,718.7 $ 5,518.0 $ 4,673.4
Schedule of Estimated Amortization Expense	The estimated remaining amortization expense of the Company’s acquired intangible assets as of December 28, 2024 for each of the five succeeding fiscal years was as follows: Remainder of Fiscal 2025 $ 148.1 Fiscal 2026 $ 169.0 Fiscal 2027 $ 81.9 Fiscal 2028 $ 78.8 Fiscal 2029 $ 73.2

Product Warranties (Tables)

Product Warranties (Tables)	3 Months Ended
	Dec. 28, 2024
Guarantees [Abstract]
Product Warranty Activity	Product warranty activity was as follows: Balance at Provisions Settlements/ Balance at Three Months Ended: December 28, 2024 $ 9.9 $ 2.4 $ (2.3) $ 10.0 December 30, 2023 $ 8.3 $ 2.9 $ (2.1) $ 9.1

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	3 Months Ended
	Dec. 28, 2024
Accumulated Other Comprehensive Income [Abstract]
Changes in Accumulated Other Comprehensive Income	The following tables summarize the changes in accumulated balances of other comprehensive income (loss) for the periods presented: Three Months Ended December 28, 2024 Foreign Currency Translation Available-For-Sale Debt Securities Hedged Interest Rate Swaps Total Beginning Balance $ (114.9) $ 1.6 $ 1.8 $ (111.5) Other comprehensive income (loss) before reclassifications (54.8) (1.3) 4.9 (51.2) Ending Balance $ (169.7) $ 0.3 $ 6.7 $ (162.7) Three Months Ended December 30, 2023 Foreign Currency Translation Pension Plans Hedged Interest Rate Swaps Total Beginning Balance $ (168.0) $ 0.3 $ 20.1 $ (147.6) Other comprehensive income (loss) before reclassifications 43.0 — (14.2) 28.8 Ending Balance $ (125.0) $ 0.3 $ 5.9 $ (118.8)

Basis of Presentation (Details)

Basis of Presentation (Details) $ in Millions	Jan. 02, 2025 USD ($)
Subsequent Event | Gynesonics, Inc.
Subsequent Event [Line Items]
Consideration transferred	$ 350

Revenue - Business Revenue (Det

Revenue - Business Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Disaggregation of Revenue [Line Items]
Revenues	$ 1,021.8	$ 1,013.1
United States
Disaggregation of Revenue [Line Items]
Revenues	757.9	753.7
International
Disaggregation of Revenue [Line Items]
Revenues	263.9	259.4
Diagnostics
Disaggregation of Revenue [Line Items]
Revenues	470.6	447.8
Diagnostics | United States
Disaggregation of Revenue [Line Items]
Revenues	342.7	325.4
Diagnostics | International
Disaggregation of Revenue [Line Items]
Revenues	127.9	122.4
Diagnostics | Cytology & Perinatal
Disaggregation of Revenue [Line Items]
Revenues	125.4	120
Diagnostics | Cytology & Perinatal | United States
Disaggregation of Revenue [Line Items]
Revenues	76	69.8
Diagnostics | Cytology & Perinatal | International
Disaggregation of Revenue [Line Items]
Revenues	49.4	50.2
Diagnostics | Molecular Diagnostics
Disaggregation of Revenue [Line Items]
Revenues	341.1	319.8
Diagnostics | Molecular Diagnostics | United States
Disaggregation of Revenue [Line Items]
Revenues	262.6	247.6
Diagnostics | Molecular Diagnostics | International
Disaggregation of Revenue [Line Items]
Revenues	78.5	72.2
Diagnostics | Blood Screening
Disaggregation of Revenue [Line Items]
Revenues	4.1	8
Diagnostics | Blood Screening | United States
Disaggregation of Revenue [Line Items]
Revenues	4.1	8
Diagnostics | Blood Screening | International
Disaggregation of Revenue [Line Items]
Revenues	0	0
Breast Health
Disaggregation of Revenue [Line Items]
Revenues	369.1	377.7
Breast Health | United States
Disaggregation of Revenue [Line Items]
Revenues	282	289.5
Breast Health | International
Disaggregation of Revenue [Line Items]
Revenues	87.1	88.2
Breast Health | Breast Imaging
Disaggregation of Revenue [Line Items]
Revenues	281.6	301.4
Breast Health | Breast Imaging | United States
Disaggregation of Revenue [Line Items]
Revenues	215.7	228.4
Breast Health | Breast Imaging | International
Disaggregation of Revenue [Line Items]
Revenues	65.9	73
Breast Health | Interventional Breast Solutions
Disaggregation of Revenue [Line Items]
Revenues	87.5	76.3
Breast Health | Interventional Breast Solutions | United States
Disaggregation of Revenue [Line Items]
Revenues	66.3	61.1
Breast Health | Interventional Breast Solutions | International
Disaggregation of Revenue [Line Items]
Revenues	21.2	15.2
GYN Surgical
Disaggregation of Revenue [Line Items]
Revenues	166.3	162.2
GYN Surgical | United States
Disaggregation of Revenue [Line Items]
Revenues	121.9	125.1
GYN Surgical | International
Disaggregation of Revenue [Line Items]
Revenues	44.4	37.1
Skeletal Health
Disaggregation of Revenue [Line Items]
Revenues	15.8	25.4
Skeletal Health | United States
Disaggregation of Revenue [Line Items]
Revenues	11.3	13.7
Skeletal Health | International
Disaggregation of Revenue [Line Items]
Revenues	$ 4.5	$ 11.7

Revenue - Geographical Revenue

Revenue - Geographical Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Disaggregation of Revenue [Line Items]
Revenues	$ 1,021.8	$ 1,013.1
United States
Disaggregation of Revenue [Line Items]
Revenues	757.9	753.7
Europe
Disaggregation of Revenue [Line Items]
Revenues	148.9	142.8
Asia-Pacific
Disaggregation of Revenue [Line Items]
Revenues	59.8	63.8
Rest of World
Disaggregation of Revenue [Line Items]
Revenues	$ 55.2	$ 52.8

Revenue - Revenue by Type (Deta

Revenue - Revenue by Type (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Disaggregation of Revenue [Line Items]
Revenues	$ 1,021.8	$ 1,013.1
Disposables
Disaggregation of Revenue [Line Items]
Revenues	663.7	628.9
Capital equipment, components and software
Disaggregation of Revenue [Line Items]
Revenues	154.2	199.2
Service
Disaggregation of Revenue [Line Items]
Revenues	198.6	178.8
Other
Disaggregation of Revenue [Line Items]
Revenues	$ 5.3	$ 6.2

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue, Remaining Performance Obligation, Amount	$ 863.7
Contract with Customer, Liability, Revenue Recognized	$ 70	$ 64.4

Revenue - Remaining Performance

Revenue - Remaining Performance Obligation (Details)	Dec. 28, 2024
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-12-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	38%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-09-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	33%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-09-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	17%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-09-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	8%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-09-29
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Percentage	4%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year

Leases - Additional Lease Infor

Leases - Additional Lease Information (Details)	3 Months Ended
	Dec. 28, 2024
Leases [Abstract]
Lease revenue as a percentage of total (percentage)	0.03

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Millions	Dec. 28, 2024	Sep. 28, 2024
Assets:
Total available-for-sale securities	$ 406.6	$ 992.9
Total	426.1	996.8
Liabilities:
Contingent consideration	1.1	1.1
Total	1.1	13.9
Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Total	406.6	992.9
Liabilities:
Contingent consideration	0	0
Total	0	0
Significant Other Observable Inputs (Level 2)
Assets:
Total	19.5	3.9
Liabilities:
Contingent consideration	0	0
Total	0	12.8
Significant Unobservable Inputs (Level 3)
Assets:
Total	0	0
Liabilities:
Contingent consideration	1.1	1.1
Total	1.1	1.1
Interest Rate Swap
Assets:
Interest rate swaps	9.4	3.1
Liabilities:
Interest Rate Cash Flow Hedge Liability at Fair Value		0.2
Interest Rate Swap | Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Interest rate swaps	0	0
Liabilities:
Interest Rate Cash Flow Hedge Liability at Fair Value		0
Interest Rate Swap | Significant Other Observable Inputs (Level 2)
Assets:
Interest rate swaps	9.4	3.1
Liabilities:
Interest Rate Cash Flow Hedge Liability at Fair Value		0.2
Interest Rate Swap | Significant Unobservable Inputs (Level 3)
Assets:
Interest rate swaps	0	0
Liabilities:
Interest Rate Cash Flow Hedge Liability at Fair Value		0
Foreign currency option contracts
Assets:
Foreign Currency Contract, Asset, Fair Value Disclosure	0.4	0.8
Foreign currency option contracts | Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Foreign currency option contracts | Significant Other Observable Inputs (Level 2)
Assets:
Foreign Currency Contract, Asset, Fair Value Disclosure	0.4	0.8
Foreign currency option contracts | Significant Unobservable Inputs (Level 3)
Assets:
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Forward foreign currency contracts
Assets:
Foreign Currency Contract, Asset, Fair Value Disclosure	9.7
Liabilities:
Foreign Currency Contracts, Liability, Fair Value Disclosure		12.6
Forward foreign currency contracts | Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Foreign Currency Contract, Asset, Fair Value Disclosure	0
Liabilities:
Foreign Currency Contracts, Liability, Fair Value Disclosure		0
Forward foreign currency contracts | Significant Other Observable Inputs (Level 2)
Assets:
Foreign Currency Contract, Asset, Fair Value Disclosure	9.7
Liabilities:
Foreign Currency Contracts, Liability, Fair Value Disclosure		12.6
Forward foreign currency contracts | Significant Unobservable Inputs (Level 3)
Assets:
Foreign Currency Contract, Asset, Fair Value Disclosure	0
Liabilities:
Foreign Currency Contracts, Liability, Fair Value Disclosure		0
Money Market Funds
Assets:
Assets:	152.1	341.7
Money Market Funds | Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Assets:	152.1	341.7
Money Market Funds | Significant Other Observable Inputs (Level 2)
Assets:
Assets:	0	0
Money Market Funds | Significant Unobservable Inputs (Level 3)
Assets:
Assets:	0	0
US Treasury Securities
Assets:
Total available-for-sale securities	254.5	626.3
US Treasury Securities | Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Total available-for-sale securities	254.5	626.3
US Treasury Securities | Significant Other Observable Inputs (Level 2)
Assets:
Total available-for-sale securities	0	0
US Treasury Securities | Significant Unobservable Inputs (Level 3)
Assets:
Total available-for-sale securities	$ 0	0
Commercial Paper
Assets:
Assets:		24.9
Commercial Paper | Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Assets:		24.9
Commercial Paper | Significant Other Observable Inputs (Level 2)
Assets:
Assets:		0
Commercial Paper | Significant Unobservable Inputs (Level 3)
Assets:
Assets:		$ 0

Fair Value Measurements - Roll

Fair Value Measurements - Roll Forward (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Fair Value Disclosures [Abstract]
Beginning balance	$ 1.1	$ 2
Contingent consideration recorded at acquisition	0	0
Fair value adjustments	0	1.7
Payments	0	0
Ending balance	$ 1.1	$ 3.7

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 30, 2023	Dec. 28, 2024
Mobidiag | Right of use asset
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Intangible asset impairment charge	$ 12.5
In-process research and development | Mobidiag
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Intangible asset impairment charge	4.3
Intangible assets, current	$ 22.4
2028 Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair value of debt instrument		$ 387.4
2029 Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair value of debt instrument		860.9
Credit Agreement
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Borrowed principal		$ 1,200
2028 Senior Notes | Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Stated interest rate		4.625%
2029 Senior Notes | Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Stated interest rate		3.25%

Fair Value Measurements - Cash

Fair Value Measurements - Cash and Cash Equivalents (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Sep. 28, 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cost	$ 1,782.1	$ 2,160.2
Short-Term Investments, Unrealized Gain	0.4
Short-Term Investments, Unrealized Loss	0
Total available-for-sale securities	406.6	992.9
Cash, Cash Equivalents, and Short-Term Investments	2,020.2
Cash, Cash Equivalents, and Short-Term Investments, Fair Value	2,020.6
Investments	238.5
Cash
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cost	1,614
Unrealized Gains	0
Unrealized Losses	0
Fair Value	1,614
Money Market Funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cost	152.1
Fair Value	152.1	341.7
Short-Term Investments, Unrealized Gain	0
Short-Term Investments, Unrealized Loss	0
Investments	0
US Treasury Securities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cost	16
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss	254.1
Investments, Unrealized Gain	0.4
Investments, Unrealized Loss	0
Total available-for-sale securities	254.5	$ 626.3
Investments	$ 238.5

Fair Value Measurements - Avail

Fair Value Measurements - Available for Sale Debt Securities (Details) - USD ($) $ in Millions	Dec. 28, 2024	Sep. 28, 2024
Fair Value Disclosures [Abstract]
Due in three months or less	$ 168.1	$ 723.1
Due after three months through one year	190.6	173.4
Due after one year through five years	47.9	96.4
Total available-for-sale securities	$ 406.6	$ 992.9

Business Combinations - Additio

Business Combinations - Additional Information (Details) - Endomag	Jul. 25, 2024 USD ($)
Business Acquisition [Line Items]
Consideration transferred	$ 313,900,000
Business Acquisition, Measurement Input	15%
Business Acquisition, Goodwill, Expected Tax Deductible Amount	$ 0
Developed technology
Business Acquisition [Line Items]
Intangible assets useful life	11 years
Trade Names
Business Acquisition [Line Items]
Intangible assets useful life	11 years
Customer Relationships
Business Acquisition [Line Items]
Intangible assets useful life	12 years

Business Combinations - Purchas

Business Combinations - Purchase Price Allocation (Details) - USD ($) $ in Millions	Dec. 28, 2024	Sep. 28, 2024	Jul. 25, 2024
Business Acquisition [Line Items]
Goodwill	$ 3,422.9	$ 3,443.1
Endomag
Business Acquisition [Line Items]
Cash			$ 16.2
Accounts receivable			5.5
Inventory			14.9
Other assets			7
Accounts payable and accrued expenses			(22.6)
Deferred income taxes, net			(43.8)
Goodwill			138.9
Purchase Price			313.9
Endomag | Developed technology
Business Acquisition [Line Items]
Identifiable intangible assets:			180.9
Endomag | Trade Names
Business Acquisition [Line Items]
Identifiable intangible assets:			7.4
Endomag | Customer Relationships
Business Acquisition [Line Items]
Identifiable intangible assets:			6.5
Endomag | In-process research and development
Business Acquisition [Line Items]
Identifiable intangible assets:			$ 3

Strategic Investments (Details)

Strategic Investments (Details) - USD ($)			3 Months Ended
	Dec. 18, 2024	Nov. 13, 2023	Dec. 28, 2024	Dec. 30, 2023	Sep. 28, 2024
Schedule of Equity Method Investments [Line Items]
Impairment loss			$ 0	$ 0
Equity securities without readily determinable fair value			30,300,000		$ 25,300,000
Maverix Medical LLC
Schedule of Equity Method Investments [Line Items]
Payments to acquire equity method investments		$ 24,500,000
Ownership percentage		45%
Equity method investments			19,500,000
Loss from equity method investments			$ 1,500,000
Capital call notice, percent of committed capital	13.30%
Committed capital	$ 9,000,000

Disposition (Details)

Disposition (Details) - Disposed of by Sale - SSI Ultrasound Imaging Business - USD ($) $ in Millions		3 Months Ended
	Sep. 28, 2023	Sep. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales price	$ 1.9
Cash divested from deconsolidation	$ 33.2
Intangible asset impairment charge		$ 51.7

Restructuring (Details)

Restructuring (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Sep. 28, 2024
Mobidiag
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accelerated depreciation		$ 7.2
Lease asset impairment charges		12.5
Severance costs	$ 1.7	1.8	$ 11.9
Expected cost	15.5
Danbury closure
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Severance costs	1.1	$ 0.5
Expected cost	$ 8.8

Borrowings and Credit Arrange_3

Borrowings and Credit Arrangements - Company's Borrowings (Detail) - USD ($) $ in Millions	Dec. 28, 2024	Sep. 28, 2024
Debt Instrument [Line Items]
Current portion of long-term debt	$ 46.8	$ 37.5
Total long-term debt obligations	2,479.2	2,497.1
Total debt obligations	2,526	2,534.6
Term Loan
Debt Instrument [Line Items]
Current portion of long-term debt	46.8	37.5
Long term debt obligations. excluding convertible notes	1,140.2	1,158.7
2028 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations. excluding convertible notes	397.7	397.6
2029 Senior Notes
Debt Instrument [Line Items]
Long term debt obligations. excluding convertible notes	$ 941.3	$ 940.8

Borrowings and Credit Arrange_4

Borrowings and Credit Arrangements - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Aug. 25, 2022	Sep. 27, 2021
Interest Rate Swap, Agreement One
Debt Instrument [Line Items]
Derivative notional amount	$ 1,000
Variable interest rate	1.23%
Interest Rate Swap, Agreement Two
Debt Instrument [Line Items]
Derivative notional amount	$ 500
Variable interest rate	3.46%
Interest Rate Swap
Debt Instrument [Line Items]
Derivative notional amount			$ 1,000
Variable interest rate			1.23%
Proceeds from swap	$ 1.6	$ 9.7
Secured Term Loan | 2021 Term Loan
Debt Instrument [Line Items]
Senior notes, face amount	1,200			$ 1,500
Revolver | 2021 Revolver
Debt Instrument [Line Items]
Revolving credit facility borrowings				$ 2,000
Senior Notes | 2028 Senior Notes
Debt Instrument [Line Items]
Senior notes, face amount	$ 400
Stated interest rate	4.625%
Senior Notes | 2029 Senior Notes
Debt Instrument [Line Items]
Stated interest rate	3.25%
Senior notes	$ 950

Borrowings and Credit Arrange_5

Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details) - Credit Agreement - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Line of Credit Facility [Line Items]
Interest expense	$ 18.9	$ 22.6
Weighted average interest rate	5.66%	6.44%
Interest rate at end of period	5.44%	6.46%

Borrowings and Credit Arrange_6

Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details) - Senior Notes - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
2028 Senior Notes
Line of Credit Facility [Line Items]
Stated interest rate	4.625%
Interest expense	$ 4.8	$ 4.8
2029 Senior Notes
Line of Credit Facility [Line Items]
Stated interest rate	3.25%
Interest expense	$ 8.2	8.2
Total
Line of Credit Facility [Line Items]
Interest expense	$ 13	$ 13

Trade Receivables and Allowan_3

Trade Receivables and Allowance for Credit Losses (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance at Beginning of Period	$ 41.4	$ 38.5
Credit Loss (Gain)	(0.3)	4.9
Write-offs, Payments and Foreign Exchange	(1)	(0.3)
Balance at End of Period	$ 40.1	$ 43.1

Derivatives - Additional Inform

Derivatives - Additional Information (Details) - USD ($) $ in Millions	Dec. 28, 2024	Mar. 23, 2023	Aug. 25, 2022
Interest rate swaps
Derivative [Line Items]
Derivative notional amount			$ 1,000
Variable interest rate			1.23%
Interest Rate Swap, 2023
Derivative [Line Items]
Derivative notional amount		$ 500
Variable interest rate		3.46%
Interest Rate Swap, 2024
Derivative [Line Items]
Derivative notional amount		$ 500
Variable interest rate		2.98%
Cash Flow Hedge Derivative Instrument Assets at Fair Value	$ 9.4
Forward and option contracts
Derivative [Line Items]
Notational Amount	$ 345.3

Derivatives - Schedule Of Chang

Derivatives - Schedule Of Change in Fair Value Of Derivative Contracts (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Total	$ 22.3	$ (11.2)
Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	0.3	1.3
Amount of unrealized gain (loss) recognized in income	22	(12.5)
Forward foreign currency contracts | Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of realized gain (loss) recognized in income	0.3	1.3
Amount of unrealized gain (loss) recognized in income	22.4	(12.5)
Foreign currency option contracts | Derivatives not designated as hedging instruments
Derivative Instruments, Gain (Loss) [Line Items]
Amount of unrealized gain (loss) recognized in income	(0.4)	$ 0
Interest Rate Swap, 2024
Derivative Instruments, Gain (Loss) [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	$ 9.4

Derivatives - Fair Value of Der

Derivatives - Fair Value of Derivative Financial Instruments (Details) - USD ($) $ in Millions	Dec. 28, 2024	Sep. 28, 2024
Derivative instruments designated as a cash flow hedge | Interest rate swaps
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Asset, Subject to Master Netting Arrangement, before Offset	$ 9.4	$ 3.1
Derivative instruments designated as a cash flow hedge | Interest rate swaps | Prepaid expenses and other current assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	5.7	3.1
Derivative instruments designated as a cash flow hedge | Interest rate swaps | Other assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	3.7	0
Derivatives not designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Asset, Subject to Master Netting Arrangement, before Offset	10.1	0.8
Derivatives not designated as hedging instruments | Interest rate swaps | Other long-term liabilities
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	0	0.2
Derivatives not designated as hedging instruments | Forward foreign currency contracts | Prepaid expenses and other current assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	9.7	0
Derivatives not designated as hedging instruments | Forward foreign currency contracts | Accrued expenses
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	0	12.6
Derivatives not designated as hedging instruments | Foreign currency option contracts | Prepaid expenses and other current assets
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	$ 0.4	$ 0.8

Derivatives - Gain (Loss) on Fa

Derivatives - Gain (Loss) on Fair Value Hedges Recognized in AOCI (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in other comprehensive income, net of taxes:	$ 4.9	$ (14.2)
Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in other comprehensive income, net of taxes:	$ 4.9	$ (14.2)

Commitments and Contingencies (

Commitments and Contingencies (Details)	Nov. 04, 2022 claim plaintiff
Commitments and Contingencies Disclosure [Abstract]
Number of plaintiffs | plaintiff	100
Pending claims, number | claim	1

Net Income Per Share (Detail)

Net Income Per Share (Detail) - shares shares in Thousands	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Earnings Per Share [Line Items]
Basic weighted average common shares outstanding	230,284	238,627
Weighted average common stock equivalents from assumed exercise of stock options and issuance of restricted stock units	1,823	1,587
Diluted weighted average common shares outstanding	232,107	240,214
Outstanding Stock Options and stock units
Weighted-average anti-dilutive shares related to:
Weighted-average anti-dilutive shares (in shares)	829	2,046

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 30.1	$ 28.7
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3.5	2.8
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2.5	3.2
Selling and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3.7	3.2
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 20.4	$ 19.5

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Stock option plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)	0.5	0.5
Weighted-average exercise prices (in dollars per share)	$ 79.38	$ 71.93
Share-based compensation, stock options outstanding (in shares)	4.6
Weighted-average exercise price of options outstanding (in dollars per share)	$ 57.88
Unrecognized compensation expense	$ 17.8
Weighted-average period for recognition of unrecognized stock-based compensation, years	2 years 4 months 24 days
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.8	0.7
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)	$ 79.88	$ 71.90
Unrecognized compensation expense	$ 89.1
Weighted-average period for recognition of unrecognized stock-based compensation, years	2 years
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)	$ 79.39	$ 71.92
PSU Free Cash Flow [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)	$ 79.39	$ 71.92
Minimum eligible percentage to receive target number of shares of company's common stock	0%
Maximum eligible percentage to receive target number of shares of company's common stock	200%
Performance stock units vesting period	3 years
Market Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted (in shares)	0.1	0.1
Restricted stock units (RSUs), weighted average grant date fair values (in dollars per share)	$ 87.41	$ 88.06
Minimum eligible percentage to receive target number of shares of company's common stock	0%
Maximum eligible percentage to receive target number of shares of company's common stock	200%
Performance stock units vesting period	3 years
RSU, PSU, MSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in shares)	1.8

Stock-Based Compensation - Weig

Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail) - USD ($)	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate	4.20%	4.40%
Expected volatility	32.50%	33.40%
Expected life (in years)	4 years 9 months 18 days	4 years 9 months 18 days
Dividend yield	$ 0	$ 0
Weighted average fair value of options granted	$ 26.74	$ 24.93

Other Balance Sheet Informati_3

Other Balance Sheet Information - Inventories (Detail) - USD ($) $ in Millions	Dec. 28, 2024	Sep. 28, 2024
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 269.4	$ 251.4
Work-in-process	60.6	62
Finished goods	377.1	366.4
Inventories	$ 707.1	$ 679.8

Other Balance Sheet Informati_4

Other Balance Sheet Information - Property, Plant and Equipment (Detail) - USD ($) $ in Millions	Dec. 28, 2024	Sep. 28, 2024
Balance Sheet Related Disclosures [Abstract]
Equipment	$ 383.2	$ 378.1
Equipment under customer usage agreements	521.8	523.1
Building and improvements	248.3	247.1
Leasehold improvements	44.4	44
Land	40.7	40.8
Furniture and fixtures	25.6	24.6
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	8.2	8.8
Property, plant and equipment, gross	1,272.2	1,266.5
Less – accumulated depreciation and amortization	(735)	(728.7)
Property, plant and equipment, net	$ 537.2	$ 537.8

Business Segments and Geograp_3

Business Segments and Geographic Information - Additional Information (Detail)	3 Months Ended
	Dec. 28, 2024 USD ($) Segment	Dec. 30, 2023 USD ($)
Segment Reporting Disclosure [Line Items]
Number of reportable segments | Segment	4
Revenues	$ 1,021,800,000	$ 1,013,100,000
Intersegment
Segment Reporting Disclosure [Line Items]
Revenues	$ 0	$ 0

Business Segments and Geograp_4

Business Segments and Geographic Information - Segment Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023	Sep. 28, 2024
Segment Reporting Information [Line Items]
Total revenues	$ 1,021.8	$ 1,013.1
Income (loss) from operations	229.8	198.2
Depreciation and amortization	74	88.4
Capital expenditures	31.6	38
Identifiable assets	8,728.7		$ 9,156
Diagnostics
Segment Reporting Information [Line Items]
Total revenues	470.6	447.8
Income (loss) from operations	118.9	49.4
Depreciation and amortization	48.6	65.9
Capital expenditures	17.8	24.2
Identifiable assets	2,412.9		2,431.3
Breast Health
Segment Reporting Information [Line Items]
Total revenues	369.1	377.7
Income (loss) from operations	67.5	102.2
Depreciation and amortization	13.2	10.3
Capital expenditures	8.9	9.3
Identifiable assets	1,556.8		1,588.9
GYN Surgical
Segment Reporting Information [Line Items]
Total revenues	166.3	162.2
Income (loss) from operations	46.6	43.2
Depreciation and amortization	12	12
Capital expenditures	3.7	4.2
Identifiable assets	1,429		1,419.9
Skeletal Health
Segment Reporting Information [Line Items]
Total revenues	15.8	25.4
Income (loss) from operations	(3.2)	3.4
Depreciation and amortization	0.2	0.2
Capital expenditures	0	0.1
Identifiable assets	44.7		48.3
Corporate
Segment Reporting Information [Line Items]
Capital expenditures	1.2	$ 0.2
Identifiable assets	$ 3,285.3		$ 3,667.6

Business Segments and Geograp_5

Business Segments and Geographic Information - Revenues by Geography (Detail)	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Schedule Of Geographical Segments [Line Items]
Revenues	100%	100%
United States
Schedule Of Geographical Segments [Line Items]
Revenues	74.20%	74.40%
Europe
Schedule Of Geographical Segments [Line Items]
Revenues	14.60%	14.10%
Asia-Pacific
Schedule Of Geographical Segments [Line Items]
Revenues	5.90%	6.30%
Rest of World
Schedule Of Geographical Segments [Line Items]
Revenues	5.30%	5.20%

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Income Tax Contingency [Line Items]
Company's effective tax rate	18.80%	(28.90%)
Provision (benefit) for income taxes	$ 46.5	$ (55.2)
Foreign Tax Jurisdiction
Income Tax Contingency [Line Items]
Provision (benefit) for income taxes		$ (107.2)

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Schedule of Intangible Assets (Detail) - USD ($) $ in Millions	Dec. 28, 2024	Sep. 28, 2024
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 5,512	$ 5,518
Accumulated Amortization	4,718.7	4,673.4
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	4,562.7	4,567
Accumulated Amortization	3,877.3	3,834
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	24.9	25.1
Accumulated Amortization	0	0
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	607.7	609.7
Accumulated Amortization	570.2	569.8
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	259.6	260.3
Accumulated Amortization	225.5	224.5
Total acquired intangible assets
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	5,454.9	5,462.1
Accumulated Amortization	4,673	4,628.3
Internal-use software
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	26	25.7
Accumulated Amortization	20.8	20.5
Capitalized software embedded in products
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	31.1	30.2
Accumulated Amortization	$ 24.9	$ 24.6

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail) $ in Millions	Dec. 28, 2024 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of Fiscal 2025	$ 148.1
Fiscal 2026	169
Fiscal 2027	81.9
Fiscal 2028	78.8
Fiscal 2029	$ 73.2

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Additional Information (Details) - USD ($)	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Indefinite-Lived Intangible Assets [Line Items]
Impairment of intangible asset	$ 0	$ 4,300,000
Mobidiag
Indefinite-Lived Intangible Assets [Line Items]
Accelerated amortization		7,300,000
Mobidiag | In-process research and development
Indefinite-Lived Intangible Assets [Line Items]
Impairment of intangible asset		4,300,000
Intangible assets, current		22,400,000
Mobidiag | Customer Relationships
Indefinite-Lived Intangible Assets [Line Items]
Finite-lived intangibles		0
Mobidiag | Trade Names
Indefinite-Lived Intangible Assets [Line Items]
Finite-lived intangibles		$ 0

Product Warranties - Product Wa

Product Warranties - Product Warranty Activity (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Balance at Beginning of Period	$ 9.9	$ 8.3
Provisions	2.4	2.9
Settlements/ Adjustments	(2.3)	(2.1)
Balance at End of Period	$ 10	$ 9.1

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 28, 2024	Dec. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	$ 5,130
Other comprehensive income (loss) before reclassifications	(51.2)	$ 28.8
Ending balance	4,773.3
Total
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(111.5)	(147.6)
Ending balance	(162.7)	(118.8)
Foreign Currency Translation
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(114.9)	(168)
Other comprehensive income (loss) before reclassifications	(54.8)	43
Ending balance	(169.7)	(125)
Pension Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance		0.3
Other comprehensive income (loss) before reclassifications		0
Ending balance		0.3
Available-For-Sale Debt Securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	1.6
Other comprehensive income (loss) before reclassifications	(1.3)
Ending balance	0.3
Hedged Interest Rate Swaps | Interest Rate Swap
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	1.8	20.1
Other comprehensive income (loss) before reclassifications	4.9	(14.2)
Ending balance	$ 6.7	$ 5.9

Share Repurchase (Details)

Share Repurchase (Details) - USD ($)					1 Months Ended	3 Months Ended
	Dec. 23, 2024	Nov. 20, 2024	Sep. 12, 2024	Sep. 22, 2022	Feb. 06, 2025	Dec. 28, 2024	Nov. 19, 2024
share repurchase plan [Line Items]
Accelerated share repurchase agreement							$ 250,000,000
Accelerated Share Repurchases, Settlement (Payment) or Receipt		$ 250,000,000
Repurchase of common stock (in shares)	800,000	2,500,000
Percentage of share repurchase program		80%
September 22, 2022
share repurchase plan [Line Items]
Share Repurchase Program, Period in Force				5 years
Share Repurchase Program, Authorized, Amount				$ 1,000,000,000
Stock Repurchased During Period, Shares						2,400,000
Stock Repurchased During Period, Value						$ 190,300,000
Share Repurchase Program, Remaining Authorized, Amount						0
December 11, 2020
share repurchase plan [Line Items]
Share Repurchase Program, Authorized, Amount						$ 1,000,000,000
September 12, 2024
share repurchase plan [Line Items]
Share Repurchase Program, Period in Force			5 years
Share Repurchase Program, Authorized, Amount			$ 1,500,000,000
Stock Repurchased During Period, Shares						1,100,000
Stock Repurchased During Period, Value						$ 77,000,000
Share Repurchase Program, Remaining Authorized, Amount						$ 1,170,000,000
September 12, 2024 | Subsequent Event
share repurchase plan [Line Items]
Stock Repurchased During Period, Shares					1,400,000
Stock Repurchased During Period, Value					$ 95,100,000